{"gene":"FRS2","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":1998,"finding":"FRS2 (FRS2alpha) forms a complex with the N-terminal SH2 domain of Shp2 upon FGF stimulation; the complex also contains Grb2 and Sos1. An FRS2 mutant deficient in both Grb2 and Shp2 binding fails to sustain MAP kinase activation and cannot induce PC12 cell differentiation in response to FGF. Shp2 catalytic activity is required for sustained ERK activation and potentiation of FGF-induced differentiation.","method":"Co-immunoprecipitation, point mutagenesis of FRS2, dominant-negative Shp2 expression, PC12 differentiation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP combined with functional mutagenesis and cell differentiation readout; replicated across multiple mutant constructs in a single rigorous study","pmids":["9632781"],"is_preprint":false},{"year":2000,"finding":"The PTB domains of FRS2alpha and FRS2beta bind directly to a highly conserved juxtamembrane sequence in FGFR1 constitutively (phosphorylation-independent), while binding to TrkA (NGF receptor) at pY490 (NPXpY motif) is phosphorylation-dependent. Thus the same PTB domain recognizes two structurally distinct receptor sequences by different mechanisms. FRS2alpha tyrosine phosphorylation in response to NGF is diminished when a kinase-inactive FGFR1 is overexpressed, indicating FGFR1 can sequester FRS2 away from TrkA.","method":"Peptide competition assays, deletion and alanine-scanning mutagenesis, phosphorylation-dependent binding assays, dominant-negative FGFR1 overexpression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro binding assays with mutagenesis and peptide competition; multiple orthogonal methods in a single rigorous study","pmids":["10629055"],"is_preprint":false},{"year":1999,"finding":"FRS2 PTB domain binds TrkA at the same phosphotyrosine residue (Y490) as Shc, suggesting competitive binding. FRS2 also binds Grb2, Crk, SH-PTP-2, p13(suc1), and the SH3 domain of Src. Overexpression of FRS2 in cells expressing a TrkA NGF-nonresponsive mutant reconstitutes NGF-induced cell cycle arrest and neuronal differentiation.","method":"cDNA cloning, co-immunoprecipitation, functional reconstitution by overexpression in mutant TrkA cells, differentiation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple binding partners identified by Co-IP, functional rescue by overexpression, replicated conceptually across multiple constructs","pmids":["10092678"],"is_preprint":false},{"year":2001,"finding":"Targeted disruption of FRS2alpha in mice causes embryonic lethality at E7.0–E7.5. FRS2alpha-deficient fibroblasts show impaired FGF-induced MAP kinase stimulation, PI3K activation, chemotaxis, and cell proliferation. Tyrosine-phosphorylated FRS2alpha assembles a multiprotein complex including Gab1. Different tyrosine phosphorylation sites on FRS2alpha mediate distinct FGF-induced biological responses.","method":"Gene knockout (homologous recombination), MEF functional assays (MAPK, PI3K, chemotaxis, proliferation), multiprotein complex assembly analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with multiple orthogonal functional readouts, embryonic lethality phenotype confirms central signaling role","pmids":["11447289"],"is_preprint":false},{"year":2001,"finding":"The FRS2 PTB domain binds RET at pY1062, the same residue that binds Shc. FRS2-RET binding is ligand-dependent for normal RET but constitutive for oncogenic RET-PTC forms, leading to constitutive FRS2 tyrosine phosphorylation and sustained MAP kinase activation. HSCR-associated loss-of-function RET mutants show impaired FRS2 binding and reduced MAP kinase activation.","method":"Co-immunoprecipitation, site-directed mutagenesis of RET (Y1062), cell proliferation and MAP kinase assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with mutagenesis, multiple oncogenic and loss-of-function mutants tested, functional MAPK readouts","pmids":["11390647"],"is_preprint":false},{"year":2001,"finding":"The FRS2 docking site on RET is pY1062; SNT/FRS2 is associated with GRB2 but not GAB1 upon RET activation (unlike Shc which associates with both GRB2 and GAB1), indicating FRS2 selectively activates RAS/MAPK but not PI3K/AKT downstream of RET.","method":"Site-directed mutagenesis of RET, co-immunoprecipitation, comparison of Shc vs FRS2 complexes","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with mutagenesis, single lab, consistent with PMID:11390647","pmids":["11360177"],"is_preprint":false},{"year":2002,"finding":"Grb2 bound to tyrosine-phosphorylated FRS2alpha recruits the E3 ubiquitin ligase Cbl through Grb2's SH3 domains, forming a ternary FRS2alpha–Grb2–Cbl complex that ubiquitinates FGFR and FRS2alpha in response to FGF, thereby attenuating FGF receptor signaling. FRS2alpha-null cells show only partial impairment of receptor downregulation, indicating redundant mechanisms.","method":"Co-immunoprecipitation, ubiquitination assays, FRS2alpha-null cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP of ternary complex with functional ubiquitination readout, knockout validation","pmids":["11997436"],"is_preprint":false},{"year":2002,"finding":"FRS2alpha is phosphorylated by MAP kinase on multiple threonine residues upon FGF stimulation (and also by insulin, EGF, PDGF without FRS2alpha tyrosine phosphorylation). Preventing FRS2alpha threonine phosphorylation results in constitutive tyrosine phosphorylation, enhanced ERK activation, cell migration, proliferation, and anchorage-independent growth, revealing a MAPK-mediated negative feedback loop controlling FRS2alpha activity.","method":"Threonine phosphorylation site mutagenesis, in vitro kinase assays, soft-agar colony formation, cell proliferation and migration assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis combined with multiple functional cellular readouts including anchorage-independent growth","pmids":["12419216"],"is_preprint":false},{"year":2001,"finding":"Alternative splicing of the FGFR1 juxtamembrane region (inclusion of VT motif) is required for FRS2 interaction with FGFR1; VT-minus isoforms cannot bind FRS2, accounting for their inability to activate ERK2.","method":"Co-immunoprecipitation with VT+ and VT- isoforms, ERK2 phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with splice isoforms plus functional ERK readout, single lab","pmids":["11729184"],"is_preprint":false},{"year":2002,"finding":"The FRS2alpha PTB domain uses thermodynamically distinct binding modes for TrkA/TrkB (enthalpy-driven, phosphotyrosine-dependent NPXpY recognition) versus FGFR1 (entropy-driven, phosphorylation-independent). NMR analysis shows the unstructured region C-terminal to the PTB domain alters PTB conformation and binding; disruption of the beta8-strand weakens FGFR interaction.","method":"Isothermal titration calorimetry, NMR spectroscopy, mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — biophysical characterization (ITC + NMR) with mutagenesis, multiple orthogonal methods","pmids":["11877385"],"is_preprint":false},{"year":2003,"finding":"FRS2 is localized exclusively to lipid raft membrane microdomains in vitro and in vivo. Serine/threonine phosphorylation of FRS2 within lipid rafts (mediated by PKC, Src family kinases, MEK1/2) indirectly reduces FRS2 tyrosine phosphorylation levels. Grb2 is recruited to lipid rafts during FGF2 signaling.","method":"Lipid raft fractionation, phosphorylation assays, inhibitor studies (PKC, Src, MEK), Grb2 co-fractionation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation with functional inhibitor studies, single lab","pmids":["12571252"],"is_preprint":false},{"year":2003,"finding":"FRS2 undergoes ERK1/2-mediated serine/threonine phosphorylation in response to EGF and FGF stimulation. ERK1/2 constitutively associates with the central portion of FRS2, while the C-terminal region is the ERK2 substrate. Inhibiting ERK1/2 enhances FRS2 tyrosine phosphorylation, demonstrating a negative feedback loop where activated ERK1/2 phosphorylates FRS2 to downregulate its tyrosine phosphorylation.","method":"MEK inhibitor (U0126), co-immunoprecipitation of ERK with FRS2, in vitro kinase assays, SDS-PAGE mobility shift","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay and Co-IP with functional inhibitor readout, single lab, consistent with PMID:12419216","pmids":["12974390"],"is_preprint":false},{"year":2004,"finding":"FGF receptor-mediated Sprouty2 phosphorylation on Y55 requires FRS2 as an intermediary; FRS2 recruits and activates Src family kinases, which then directly phosphorylate Sprouty2. Phospho-Sprouty2 forms a complex with Src and inhibits ERK pathway activation.","method":"Src inhibitor, mutant cell lines, co-immunoprecipitation of Src–Sprouty2 complex, FRS2-dependent Src activation assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition and mutant cells with multiple functional readouts, single lab","pmids":["15564375"],"is_preprint":false},{"year":2004,"finding":"Shp2-binding tyrosine sites on FRS2alpha are critical for retinal and lens induction in vivo: Frs2alpha(2F/2F) mice (Shp2-binding sites mutated) develop anophthalmia/microphthalmia with reduced pERK and decreased Pax6, Six3, Chx10 and Bmp4 expression, while Frs2alpha(4F/4F) (Grb2-binding sites mutated) mice show normal early eye development.","method":"Knock-in point mutation mice, immunohistochemistry, in vivo ERK activation measurement, marker gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with multiple molecular and phenotypic readouts, clean comparison of two distinct mutant alleles","pmids":["15569927"],"is_preprint":false},{"year":2005,"finding":"FRS2alpha directly associates with Rnd1 (and FRS2beta does as well); FRS2beta interaction with Rnd1 suppresses Rnd1's inhibitory effect on RhoA. Upon FGFR1 activation and FRS2beta tyrosine phosphorylation, Shp2 is recruited to FRS2beta and displaces Rnd1; liberated Rnd1 then inhibits RhoA activity to promote neurite outgrowth.","method":"Direct protein binding (pulldown/Co-IP), FGFR1 phosphorylation assays, RhoA activity assays, siRNA knockdown of Rnd1, neurite outgrowth assay in PC12 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding plus RhoA functional assay plus siRNA knockdown, single lab","pmids":["15738000"],"is_preprint":false},{"year":2005,"finding":"Disruption of Shp2-binding sites on FRS2alpha (Frs2alpha(2F)) in mice causes severe cortical development defects due to loss of intermediate progenitor cells. FRS2alpha is essential for FGF2-responsive neural progenitor cell proliferation but not for self-renewal capacity after FGF2 stimulation.","method":"Knock-in point mutation mice, BrdU labeling, neurosphere assay, histological analysis of cortex","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knock-in with multiple cellular and molecular readouts","pmids":["16239343"],"is_preprint":false},{"year":1999,"finding":"FRS2 associates with atypical protein kinase C lambda (PKClambda) in Swiss 3T3 cells stimulated with bFGF; PKC zeta also binds FRS2. The interaction is likely direct (yeast two-hybrid). Activated PKClambda (constitutively active A120E mutant) shows greater than 2-fold higher FRS2 binding than wild-type. In vitro kinase assays show FRS2 is not a substrate for PKClambda or PKCzeta, suggesting FRS2 acts as an anchoring/targeting protein for activated atypical PKCs at the plasma membrane.","method":"Co-immunoprecipitation, yeast two-hybrid, in vitro kinase assay, constitutively active PKClambda mutant","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus in vitro kinase assay, single lab","pmids":["10383403"],"is_preprint":false},{"year":2007,"finding":"FRS2alpha is required for separation, migration, and survival of pharyngeal-endoderm-derived organs (thyroid, ultimobranchial body, parathyroid, thymus) in Frs2alpha(2F/2F) mice; organ-specific differentiation markers are initially expressed normally, indicating FRS2alpha mediates migration but not initial specification of these organs.","method":"Knock-in point mutation mice (Shp2-binding site), histology, immunostaining for differentiation markers at sequential developmental stages","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model with multiple marker analyses and temporal staging, single lab","pmids":["19235715"],"is_preprint":false},{"year":2008,"finding":"FRS2alpha ablation in mesodermal outflow tract progenitors (second heart field) impairs their expansion, causing outflow tract misalignment/hypoplasia, and also causes defective endothelial-to-mesenchymal transition and impaired neural crest recruitment, resulting in outflow tract septation defects.","method":"Conditional knockout using Cre/loxP, histology, lineage tracing, immunostaining","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific knockout with multiple phenotypic readouts, single lab","pmids":["18832393"],"is_preprint":false},{"year":2008,"finding":"FRS2alpha loss-of-function FGFR2 IIIb C3 variant (Y770F mutation) causes persistent FRS2 binding to FGFR2 IIIb, enhanced FRS2 tyrosine phosphorylation, and increased transforming activity. FRS2 binding to FGFR2 IIIb is required for Y770F-mediated enhanced transformation, establishing that persistent FRS2 engagement drives oncogenic signaling.","method":"Site-directed mutagenesis of FGFR2 (Y770F, L773A), Co-IP of FRS2–FGFR2 complex, focus formation/transformation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis combined with functional transformation assays and Co-IP, single lab","pmids":["19103595"],"is_preprint":false},{"year":2010,"finding":"EphA4 directly interacts with the FRS2alpha PTB domain upon phosphorylation of the EphA4 juxtamembrane domain; EphA4 directly phosphorylates FRS2alpha in vitro. A ternary complex of EphA4, FGFR, and FRS2alpha forms, with FRS2alpha and EphA4 binding to different regions of the FGFR juxtamembrane domain simultaneously. Dominant-negative EphA4 or truncated FRS2alpha lacking tyrosine phosphorylation sites inhibit ligand-dependent proliferation of embryonic neural stem/progenitor cells.","method":"Yeast two-hybrid, in vitro binding assay, in vitro kinase assay, dominant-negative constructs, neural stem cell proliferation assay","journal":"Genes to cells","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro binding and kinase assays with functional cellular readout, single lab","pmids":["20184660"],"is_preprint":false},{"year":2010,"finding":"FRS2alpha mediates FGF4-induced ERK activation in trophoblast stem cells to enhance Cdx2 expression; Cdx2 binds an FGF4-responsive enhancer in the Bmp4 promoter, driving Bmp4 production. Exogenous Bmp4 rescues defective growth of Frs2alpha-null inner cell mass, establishing a paracrine FRS2alpha–ERK–Cdx2–Bmp4 axis.","method":"Frs2alpha-null ES/TS cell culture, ChIP for Cdx2 on Bmp4 promoter, Bmp4 rescue experiment, ERK phosphorylation assays","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus genetic rescue plus signaling assays, single lab","pmids":["19890878"],"is_preprint":false},{"year":2011,"finding":"FRS2alpha-mediated FGF signaling suppresses autophagy through the PI3K/Akt/mTOR pathway in mouse embryonic fibroblasts. Loss of FRS2alpha increases autophagy and promotes premature differentiation of cardiac progenitor cells.","method":"Frs2alpha conditional knockout in heart progenitors, embryoid body culture, autophagy markers (LC3), PI3K/Akt/mTOR inhibitor studies in Frs2alpha-null MEFs","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with pharmacological pathway dissection and multiple cellular readouts, single lab","pmids":["22207710"],"is_preprint":false},{"year":2011,"finding":"FRS2alpha-mediated FGF signaling activates mTOR via PI3K/Akt and suppresses autophagy in MEFs; the PI3K/Akt–mTOR axis is the downstream mediator of FGF's autophagy suppression.","method":"Frs2alpha-null MEFs, PI3K/Akt/mTOR inhibitor studies, autophagy marker assays (LC3 conversion)","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null cells with pharmacological pathway inhibition, single lab","pmids":["21927580"],"is_preprint":false},{"year":2001,"finding":"Xenopus FRS2 (xFRS2) is tyrosine-phosphorylated in early embryos; overexpression of unphosphorylatable xFRS2 interferes with FGF-dependent mesoderm formation. Src family kinase Laloo binds xFRS2, promotes its tyrosine phosphorylation, and both associate with Xenopus FGFR1, placing FRS2 in a Laloo–FGFR1 signaling complex required for mesoderm induction.","method":"Xenopus overexpression/dominant-negative experiments, Co-immunoprecipitation of xFRS2 with Laloo and FGFR1, tyrosine phosphorylation assay","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with dominant-negative functional readout in Xenopus embryo, single lab","pmids":["11463744"],"is_preprint":false},{"year":2001,"finding":"Xenopus SNT-1/FRS2alpha induces mesoderm in ectodermal explants, synergizes with FGF, and requires Ras activity; dominant-inhibitory SNT-1 blocks FGF-mediated mesoderm induction and disrupts axis formation in vivo. SNT-1 physically associates with Src-like kinase Laloo, and SNT-1 activity is required for Laloo-induced mesoderm induction.","method":"Xenopus embryo explant assay, dominant-negative constructs, co-immunoprecipitation, Ras inhibition","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional epistasis in Xenopus embryo with Co-IP, single lab, consistent with PMID:11463744","pmids":["11731233"],"is_preprint":false},{"year":2002,"finding":"Xenopus FRS2 (XFRS2) is essential for FGF receptor-induced oocyte maturation (germinal vesicle breakdown). Co-expression of activated XFGFR1 and XFRS2 requires MEK activity (not needed for progesterone-induced GVBD) and PI3K activity for H1 kinase activation at metaphase II. Sprouty2 acts upstream of or parallel to Raf (downstream of Ras) to inhibit XFGFR1/XFRS2-induced MAPK activation and GVBD.","method":"Xenopus oocyte microinjection, dominant-negative kinase suppressor of Ras, PI3K inhibitor (LY294002), GVBD and H1 kinase assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic/pharmacological epistasis in oocyte system with biochemical readouts, single lab","pmids":["12082104"],"is_preprint":false},{"year":2007,"finding":"FRS2 selectively recruits RET to focal complexes/membrane foci, activating Src family kinases and FAK to drive cell migration. Competitive recruitment of FRS2 vs. other adaptors to Y1062 in RET determines migration outcome; Src activation requires direct interaction at Y981, and both Y1062 (FRS2) and Y981 (Src) signals act in concert to regulate migration.","method":"Co-immunoprecipitation, focal complex localization by microscopy, Src/FAK activation assays, RET mutagenesis (Y1062, Y981)","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with mutagenesis and subcellular localization readout, functional migration assay, single lab","pmids":["18189271"],"is_preprint":false},{"year":2014,"finding":"FRS2alpha plays a critical role in VEGF receptor signaling: in vitro, FRS2alpha regulates VEGF-A and VEGF-C-dependent ERK activation and endothelial cell migration/proliferation; in vivo, endothelial-specific deletion of FRS2alpha profoundly impairs postnatal vascular development, angiogenesis, lymphangiogenesis, and arteriogenesis.","method":"Endothelial-specific conditional knockout (Cre/loxP), in vitro VEGF signaling assays, in vivo angiogenesis/lymphangiogenesis phenotyping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific knockout with multiple in vitro and in vivo readouts across vascular, lymphatic and arterial systems","pmids":["24706887"],"is_preprint":false},{"year":2014,"finding":"The FRS2alpha PTB domain has two adjacent but distinct binding pockets: one for the non-phosphorylated FGFR juxtamembrane region and one for phosphorylated TrkA/TrkB (NPXpY), enabling mutually exclusive interaction with each receptor class. NMR structure of FRS2alpha PTB bound to phosphorylated TrkB is reported.","method":"NMR structure determination, binding pocket analysis","journal":"Proteins","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with functional validation of two binding pockets; single lab but structural data","pmids":["24470253"],"is_preprint":false},{"year":2019,"finding":"FRS2alpha is N-myristoylated and also palmitoylated at cysteines 4 and 5. Mutation of C4/C5 impairs plasma membrane localization. Abolishing myristoylation (G2A mutation) also abrogates palmitoylation, indicating coupled myristoylation-dependent palmitoylation; signaling defects of the G2A mutant may thus be due to loss of palmitoylation rather than myristoylation alone.","method":"Palmitoylation assays, site-directed mutagenesis (C4A/C5A, G2A), fluorescence fluctuation spectroscopy (plasma membrane localization quantification)","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical palmitoylation assay with mutagenesis and quantitative fluorescence microscopy, single lab","pmids":["31184863"],"is_preprint":false},{"year":2018,"finding":"Loss of FRS2alpha myristoylation (using N-myristoyltransferase inhibitor B13) suppresses FGF/FGFR-mediated oncogenic signaling, inhibits FGF10-induced tumorigenesis, and reduces PI3K/MAPK signaling downstream of both wild-type and drug-resistant FGFR mutants. B13 inhibits FRS2alpha phosphorylation and mildly alters its plasma membrane localization.","method":"N-myristoyltransferase inhibitor (B13), FRS2alpha phosphorylation assays, xenograft tumor model, cell proliferation/migration assays, combination with FGFR inhibitor","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with in vitro and in vivo tumor readouts, single lab","pmids":["29540482"],"is_preprint":false},{"year":2007,"finding":"FGFR1 tyrosine autophosphorylation is required for optimal binding to full-length FRS2alpha but not to FRS2beta; the PTB domain of FRS2alpha alone binds FGFR1 constitutively, indicating the C-terminal region of FRS2alpha inhibits PTB–FGFR1 interaction that is relieved by receptor kinase activation. The Grb2-binding sites of FRS2alpha are essential for mediating FGFR1 signals to activate the FiRE enhancer.","method":"Co-immunoprecipitation in mammalian cells with recombinant proteins, FGFR1 kinase-dead and tyrosine substitution mutants, PTB domain truncation constructs, FiRE enhancer reporter assay","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with multiple receptor and adaptor mutants plus reporter assay, single lab","pmids":["17901128"],"is_preprint":false},{"year":2014,"finding":"FRS2 promotes neurotrophin-induced neurite outgrowth and branching in primary cortical neurons via both Grb2- and Shp2-dependent pathways. FRS2 binds Gab1 and Gab2 through Grb2, providing an indirect route to PI3K and Shp2. Loss of Shp2 binding reduces BDNF-induced MAPK activation; loss of either Grb2 or Shp2 binding impairs neuronal growth. FRS3 overexpression does not stimulate neuronal growth.","method":"Recombinant adenovirus overexpression of FRS2 mutants, primary cortical neuron culture, neurite outgrowth quantification, Co-IP of Gab1/Gab2 complexes","journal":"Journal of molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional mutant FRS2 constructs in primary neurons with Co-IP evidence, single lab","pmids":["25159185"],"is_preprint":false},{"year":2019,"finding":"FRS2α deletion in endothelial cells induces endothelial-to-mesenchymal transition (EndMT) by activating TGFβ signaling in a miRNA let-7-dependent manner in adult endothelium; during embryonic AV cushion morphogenesis early Frs2α deletion impairs EndMT in AV cushions, while late deletion (E10.5) has no effect, identifying FRS2α as a developmental stage-specific controller of cell fate transition.","method":"Inducible endothelial-specific conditional knockout (FRS2αiECKO at E7.5 vs E10.5), histological and molecular analysis of AV valves","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible conditional knockout with temporal staging, single lab","pmids":["31669335"],"is_preprint":false},{"year":2000,"finding":"FRS2 is phosphorylated by the insulin receptor (IR) in vitro using purified IR; insulin stimulates tyrosine phosphorylation of endogenous FRS2 in PC12/IR cells and promotes FRS2–Shp2 complex formation. FRS2 was isolated as a potential IR substrate by yeast two-hybrid screening with the Shp2 SH2 domain dependent on active IR.","method":"Yeast two-hybrid (Shp2 SH2 domain bait, IR-dependent), in vitro IR kinase assay with GST-FRS2, Co-immunoprecipitation in PC12/IR cells","journal":"Endocrinology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid plus in vitro kinase assay, no clear demonstration that this is a primary physiological mechanism; single lab","pmids":["10650943"],"is_preprint":false},{"year":2014,"finding":"FRS2α in hepatocytes is required for FGF15/FGF19-FGFR4 signaling to repress Cyp7a1 expression and limit bile acid production after prandial activity. Ablation of hepatocyte Frs2α alleles abolishes FGFR4-mediated Cyp7a1 regulation.","method":"Hepatocyte-specific Frs2α conditional knockout, Cyp7a1 mRNA quantification, FGFR4 gain/loss-of-function experiments","journal":"Current molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific knockout with biochemical pathway readout, single lab","pmids":["25056539"],"is_preprint":false},{"year":2025,"finding":"FRS2 and Shp2 deletion primarily impairs later lens vesicle development (fiber cell differentiation) rather than lens induction. Shc1 is phosphorylated at Grb2-binding sites downstream of FGF signaling; Shc1 deletion exacerbates the lens vesicle defect caused by Frs2 and Shp2 deletion, establishing Shc1 as a collaborator with Frs2 and Shp2 in recruiting Grb2 to the FGF signaling complex.","method":"Conditional knockout of Frs2, Shp2, Shc1 individually and in combination, MAPK signaling assays, lens developmental phenotype analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional knockouts combined with signaling readouts, genetic epistasis with three interacting components","pmids":["40327534"],"is_preprint":false},{"year":2023,"finding":"The FRS2 PTB domain folds via a mechanism involving an intermediate; binding to unphosphorylated FGFR1 peptide and phosphorylated TrkB peptide is electrostatic in nature (modulated by ionic strength). Site-directed mutagenesis identified specific residues involved in early and late binding events for each ligand.","method":"Equilibrium and kinetic folding assays, kinetic binding experiments at varied ionic strengths, site-directed mutagenesis","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro biophysical characterization with mutagenesis, single lab","pmids":["37543351"],"is_preprint":false}],"current_model":"FRS2alpha (FRS2) is a lipid-anchored (myristoylated and palmitoylated) scaffold/docking protein that constitutively associates via its PTB domain with the juxtamembrane region of FGF receptors (phosphorylation-independent) and, in a phosphorylation-dependent manner, with activated TrkA/B and RET receptors; upon receptor activation FRS2alpha is multiply tyrosine-phosphorylated, recruiting Grb2 (directly) and Shp2 (directly) to coordinate assembly of a multiprotein complex (including Gab1, Sos, Cbl) that drives sustained Ras/ERK and PI3K/Akt signaling, while MAP kinase-mediated threonine phosphorylation of FRS2alpha and Cbl-mediated ubiquitination of the receptor constitute negative feedback loops; FRS2alpha additionally signals through Src family kinases (to phosphorylate Sprouty2), anchors atypical PKCs, and recruits Rnd1 to modulate RhoA activity, and is required for FGF-dependent processes including embryogenesis, organogenesis (lens, heart, thyroid, kidney), neural progenitor maintenance, angiogenesis/lymphangiogenesis downstream of VEGF receptors, and bile acid homeostasis downstream of FGFR4."},"narrative":{"mechanistic_narrative":"FRS2 (FRS2alpha) is a lipid-anchored docking protein that nucleates assembly of signaling complexes downstream of receptor tyrosine kinases to drive sustained Ras/ERK and PI3K/Akt activation required for development and growth [PMID:9632781, PMID:11447289]. Its PTB domain engages two structurally distinct receptor classes by different mechanisms: it binds the juxtamembrane region of FGFR1 constitutively (phosphorylation-independent, entropy-driven) and the NPXpY motifs of activated TrkA/TrkB (pY490) and RET (pY1062) in a phosphorylation-dependent manner, using adjacent but distinct binding pockets that make these interactions mutually exclusive [PMID:10629055, PMID:11877385, PMID:24470253]. Upon receptor activation FRS2alpha is multiply tyrosine-phosphorylated, directly recruiting Grb2 and Shp2 to build a multiprotein complex including Gab1, Sos, and Cbl; the Shp2-binding sites drive sustained ERK and PI3K signaling while Grb2 brings in the E3 ligase Cbl to ubiquitinate the receptor and FRS2alpha as negative feedback [PMID:9632781, PMID:11447289, PMID:11997436]. A second feedback layer operates through MAP kinase/ERK1/2-mediated threonine phosphorylation of FRS2alpha, which dampens its own tyrosine phosphorylation and restrains ERK output, proliferation, and anchorage-independent growth [PMID:12419216, PMID:12974390]. Membrane localization is conferred by N-myristoylation coupled to palmitoylation at Cys4/Cys5, which targets FRS2alpha to lipid rafts where signaling assembly occurs [PMID:12571252, PMID:31184863]. Genetically, FRS2alpha is essential for embryogenesis and FGF-dependent organogenesis, with Shp2-binding sites specifically required for eye/lens induction, cortical neural progenitor expansion, and pharyngeal organ migration [PMID:11447289, PMID:15569927, PMID:16239343, PMID:19235715], and it additionally transduces VEGF receptor signals controlling angiogenesis and lymphangiogenesis and FGFR4 signals controlling bile acid homeostasis [PMID:24706887, PMID:25056539]. Persistent FRS2 engagement by oncogenic receptor variants drives transformation, making it a node in RTK-driven cancer [PMID:19103595, PMID:29540482].","teleology":[{"year":1998,"claim":"Established that FRS2 functions as a docking protein whose recruitment of both Shp2 and Grb2 is required to convert transient into sustained ERK signaling and drive differentiation.","evidence":"Co-IP, FRS2 point mutagenesis and dominant-negative Shp2 in PC12 differentiation assays","pmids":["9632781"],"confidence":"High","gaps":["Did not resolve which individual tyrosines bind Grb2 versus Shp2","Mechanism of receptor engagement not addressed"]},{"year":1999,"claim":"Showed FRS2 couples to the NGF receptor TrkA at the same phosphotyrosine as Shc and can functionally reconstitute neuronal differentiation, defining FRS2 as a shared RTK adaptor.","evidence":"cDNA cloning, Co-IP of multiple partners, functional rescue in NGF-nonresponsive TrkA mutant cells","pmids":["10092678"],"confidence":"High","gaps":["Competition with Shc not quantified","FGF receptor binding mode not yet contrasted"]},{"year":1999,"claim":"Identified FRS2 as an anchoring protein for activated atypical PKCs rather than a substrate, expanding its role beyond ERK adaptor functions.","evidence":"Yeast two-hybrid, Co-IP and in vitro kinase assays with constitutively active PKClambda","pmids":["10383403"],"confidence":"Medium","gaps":["Physiological consequence of aPKC anchoring not defined","Single lab"]},{"year":2000,"claim":"Resolved the dual binding logic of the PTB domain: constitutive phosphorylation-independent binding to FGFR1 versus phosphotyrosine-dependent binding to TrkA, with FGFR1 able to sequester FRS2.","evidence":"Peptide competition, alanine-scanning mutagenesis, phosphorylation-dependent binding assays","pmids":["10629055"],"confidence":"High","gaps":["Structural basis of the two modes not resolved here","In vivo relevance of sequestration untested"]},{"year":2001,"claim":"Demonstrated FRS2alpha is essential for FGF signaling and embryogenesis, with distinct tyrosine sites mediating distinct responses, establishing its non-redundant developmental role.","evidence":"Mouse knockout (E7.0-7.5 lethality), MEF assays for MAPK/PI3K/chemotaxis/proliferation, complex assembly analysis","pmids":["11447289"],"confidence":"High","gaps":["Tissue-specific requirements not separable in a global null","Site-specific phenotypes only correlative at this stage"]},{"year":2001,"claim":"Showed FRS2 docks on RET at pY1062 and that constitutive engagement by oncogenic RET-PTC drives sustained MAPK, while HSCR loss-of-function mutants impair FRS2 binding, linking FRS2 to RET-driven disease.","evidence":"Co-IP, RET Y1062 mutagenesis, oncogenic and loss-of-function mutant panels, MAPK/proliferation assays","pmids":["11390647","11360177"],"confidence":"High","gaps":["FRS2 selectivity for RAS/MAPK over PI3K only inferred from complex composition","Adaptor competition at Y1062 not quantified"]},{"year":2001,"claim":"Established that an alternatively spliced FGFR1 juxtamembrane VT motif is required for FRS2 binding and ERK activation, linking receptor isoform choice to FRS2 coupling.","evidence":"Co-IP with VT+/VT- isoforms and ERK2 assays","pmids":["11729184"],"confidence":"Medium","gaps":["Single lab","Physiological prevalence of VT- isoforms not assessed"]},{"year":2001,"claim":"Placed FRS2 in a Src-family kinase (Laloo)-FGFR1 complex required for mesoderm induction and axis formation in vivo.","evidence":"Xenopus overexpression/dominant-negative, Co-IP with Laloo and FGFR1, Ras epistasis, explant assays","pmids":["11463744","11731233"],"confidence":"Medium","gaps":["Direct kinase-substrate relationship not fully defined","Model-organism context"]},{"year":2002,"claim":"Defined a MAP kinase-mediated negative feedback loop: ERK phosphorylates FRS2alpha on threonines to suppress its tyrosine phosphorylation, restraining proliferation and transformation.","evidence":"Threonine site mutagenesis, in vitro kinase assays, soft-agar and migration/proliferation assays","pmids":["12419216","12974390"],"confidence":"High","gaps":["Stoichiometry and kinetics of feedback in vivo unclear","Specific threonines mapped only partially"]},{"year":2002,"claim":"Identified Grb2-bridged recruitment of the E3 ligase Cbl as a feedback mechanism ubiquitinating FGFR and FRS2alpha, with redundant downregulation routes.","evidence":"Co-IP of ternary FRS2-Grb2-Cbl complex, ubiquitination assays, FRS2-null cells","pmids":["11997436"],"confidence":"High","gaps":["Identity of redundant downregulation pathway unknown","Ubiquitination sites not mapped"]},{"year":2002,"claim":"Provided the biophysical basis for dual receptor recognition: enthalpy-driven phosphotyrosine binding to Trk versus entropy-driven phosphorylation-independent binding to FGFR1, with the C-terminal region modulating PTB conformation.","evidence":"Isothermal titration calorimetry, NMR, mutagenesis","pmids":["11877385"],"confidence":"High","gaps":["High-resolution structure of FGFR1-bound state not determined here","Functional consequence of C-terminal autoinhibition in cells untested"]},{"year":2003,"claim":"Localized FRS2 to lipid rafts and showed serine/threonine phosphorylation within rafts (PKC/Src/MEK) suppresses tyrosine phosphorylation, integrating membrane microdomain context with feedback regulation.","evidence":"Lipid raft fractionation, inhibitor studies, Grb2 co-fractionation","pmids":["12571252"],"confidence":"Medium","gaps":["Mechanism of raft targeting not yet molecular","Single lab"]},{"year":2004,"claim":"Defined FRS2 as the intermediary that recruits and activates Src family kinases to phosphorylate Sprouty2, wiring FRS2 into ERK pathway feedback inhibition.","evidence":"Src inhibitor, mutant cells, Co-IP of Src-Sprouty2, FRS2-dependent Src activation","pmids":["15564375"],"confidence":"Medium","gaps":["Direct FRS2-Src binding interface not mapped","Single lab"]},{"year":2004,"claim":"Used allele-specific knock-in mice to show Shp2-binding (not Grb2-binding) sites on FRS2alpha are required for eye/lens induction via ERK and downstream eye-field genes.","evidence":"Frs2alpha 2F/2F vs 4F/4F knock-in mice, IHC, in vivo pERK, marker gene analysis","pmids":["15569927"],"confidence":"High","gaps":["Why Grb2 sites are dispensable here not explained","Cell-autonomy not fully resolved"]},{"year":2005,"claim":"Extended the Shp2-site requirement to cortical neural progenitor proliferation, distinguishing FRS2-dependent proliferation from FGF2-induced self-renewal.","evidence":"Frs2alpha 2F knock-in mice, BrdU, neurosphere assays, cortical histology","pmids":["16239343"],"confidence":"High","gaps":["Molecular distinction between proliferation and self-renewal pathways unclear"]},{"year":2005,"claim":"Revealed a non-ERK output: FRS2 binds Rnd1 and, upon Shp2 recruitment displacing Rnd1, modulates RhoA activity to promote neurite outgrowth.","evidence":"Direct binding/pulldown, RhoA activity assays, Rnd1 siRNA, PC12 neurite outgrowth","pmids":["15738000"],"confidence":"Medium","gaps":["In vivo relevance of Rnd1-RhoA arm untested","Single lab"]},{"year":2007,"claim":"Clarified that the FRS2alpha C-terminal region autoinhibits PTB-FGFR1 binding, relieved by receptor kinase activation, and that Grb2 sites mediate FiRE enhancer activation.","evidence":"Co-IP with kinase-dead/tyrosine FGFR1 mutants, PTB truncations, reporter assay","pmids":["17901128"],"confidence":"Medium","gaps":["Conformational mechanism of relief not structurally resolved","Single lab"]},{"year":2007,"claim":"Showed FRS2 recruits RET to focal complexes to activate Src/FAK and drive migration, with adaptor competition at Y1062 dictating outcome.","evidence":"Co-IP, focal complex microscopy, Src/FAK assays, RET Y1062/Y981 mutagenesis, migration assays","pmids":["18189271"],"confidence":"Medium","gaps":["Quantitative competition model not established","Single lab"]},{"year":2007,"claim":"Demonstrated FRS2alpha (via Shp2 sites) is required for migration but not initial specification of pharyngeal-endoderm organs, separating its roles in morphogenesis from cell fate.","evidence":"Frs2alpha 2F/2F mice, staged histology and differentiation marker immunostaining","pmids":["19235715"],"confidence":"Medium","gaps":["Migration effector pathway downstream of FRS2 not identified","Single lab"]},{"year":2008,"claim":"Established cell-type-specific requirements for FRS2alpha in cardiac outflow tract development, including progenitor expansion and EndMT.","evidence":"Conditional knockout, histology, lineage tracing, immunostaining","pmids":["18832393"],"confidence":"Medium","gaps":["Receptor(s) upstream in this context not defined","Single lab"]},{"year":2008,"claim":"Showed persistent FRS2 engagement by an oncogenic FGFR2 IIIb Y770F variant is required for enhanced transformation, establishing FRS2 as an oncogenic driver node.","evidence":"FGFR2 mutagenesis (Y770F/L773A), Co-IP, focus formation assays","pmids":["19103595"],"confidence":"Medium","gaps":["Downstream effectors of the persistent complex not dissected","Single lab"]},{"year":2010,"claim":"Identified EphA4 as a direct FRS2alpha PTB partner and kinase, forming a ternary EphA4-FGFR-FRS2alpha complex that supports neural progenitor proliferation.","evidence":"Yeast two-hybrid, in vitro binding and kinase assays, dominant-negative constructs, NSC proliferation assay","pmids":["20184660"],"confidence":"Medium","gaps":["In vivo requirement of the ternary complex untested","Single lab"]},{"year":2010,"claim":"Defined a paracrine FRS2alpha-ERK-Cdx2-Bmp4 axis in trophoblast stem cells supporting inner cell mass growth.","evidence":"Frs2alpha-null ES/TS cells, ChIP on Bmp4 promoter, Bmp4 rescue, ERK assays","pmids":["19890878"],"confidence":"Medium","gaps":["Generalizability beyond TS cells unclear","Single lab"]},{"year":2011,"claim":"Linked FRS2alpha-FGF signaling to autophagy suppression via PI3K/Akt/mTOR, with loss promoting premature cardiac progenitor differentiation.","evidence":"Conditional knockout and Frs2alpha-null MEFs, LC3 assays, PI3K/Akt/mTOR inhibitors","pmids":["22207710","21927580"],"confidence":"Medium","gaps":["Direct molecular link between FRS2 and mTOR not mapped","Single lab cluster"]},{"year":2014,"claim":"Extended FRS2alpha function to VEGF receptor signaling, showing it is required in endothelium for angiogenesis, lymphangiogenesis, and arteriogenesis.","evidence":"Endothelial-specific conditional knockout, in vitro VEGF signaling, in vivo vascular phenotyping","pmids":["24706887"],"confidence":"High","gaps":["Direct VEGFR-FRS2 binding mode not characterized","Single lab"]},{"year":2014,"claim":"Established FRS2alpha as the hepatocyte adaptor required for FGF15/19-FGFR4 repression of Cyp7a1 and bile acid homeostasis.","evidence":"Hepatocyte-specific knockout, Cyp7a1 mRNA quantification, FGFR4 gain/loss-of-function","pmids":["25056539"],"confidence":"Medium","gaps":["Downstream transcriptional effectors of Cyp7a1 repression not defined","Single lab"]},{"year":2014,"claim":"Provided structural confirmation of two distinct adjacent PTB binding pockets enabling mutually exclusive FGFR versus Trk engagement.","evidence":"NMR structure of PTB bound to phosphorylated TrkB, binding pocket analysis","pmids":["24470253"],"confidence":"High","gaps":["FGFR-bound structure complementary to TrkB structure not solved","Allosteric coupling between pockets unresolved"]},{"year":2014,"claim":"Showed FRS2 drives neurotrophin-induced neurite outgrowth through both Grb2 and Shp2 pathways, with Grb2 bridging to Gab1/Gab2 and PI3K, and that FRS3 cannot substitute.","evidence":"Adenoviral FRS2 mutant overexpression in primary cortical neurons, neurite quantification, Gab1/Gab2 Co-IP","pmids":["25159185"],"confidence":"Medium","gaps":["Basis for FRS3 inability not explained","Overexpression context"]},{"year":2019,"claim":"Defined the membrane-anchoring mechanism: coupled N-myristoylation and Cys4/Cys5 palmitoylation are required for plasma membrane localization, with myristoylation a prerequisite for palmitoylation.","evidence":"Palmitoylation assays, G2A/C4A/C5A mutagenesis, fluorescence fluctuation spectroscopy","pmids":["31184863"],"confidence":"Medium","gaps":["Identity of the palmitoyltransferase unknown","Single lab"]},{"year":2018,"claim":"Showed pharmacological inhibition of FRS2alpha myristoylation suppresses FGFR-driven oncogenic signaling and tumorigenesis, nominating membrane anchoring as a therapeutic target.","evidence":"N-myristoyltransferase inhibitor B13, phosphorylation assays, xenograft model, FGFR inhibitor combination","pmids":["29540482"],"confidence":"Medium","gaps":["B13 specificity for FRS2 versus other myristoylated proteins not isolated","Single lab"]},{"year":2019,"claim":"Identified FRS2alpha as a developmental-stage-specific controller of EndMT, restraining TGFbeta signaling in a let-7-dependent manner.","evidence":"Inducible endothelial-specific knockout at E7.5 vs E10.5, histological/molecular AV valve analysis","pmids":["31669335"],"confidence":"Medium","gaps":["Mechanism linking FRS2 loss to let-7/TGFbeta not fully defined","Single lab"]},{"year":2023,"claim":"Characterized the folding pathway and electrostatic, ionic-strength-dependent binding kinetics of the PTB domain for both FGFR1 and TrkB ligands.","evidence":"Equilibrium/kinetic folding and binding assays at varied ionic strength, site-directed mutagenesis","pmids":["37543351"],"confidence":"Medium","gaps":["Cellular relevance of folding intermediate unknown","Single lab"]},{"year":2025,"claim":"Refined the lens model: FRS2 and Shp2 act mainly in fiber cell differentiation, and Shc1 collaborates with them to recruit Grb2, defining a partially redundant Grb2-recruitment module.","evidence":"Combinatorial conditional knockouts of Frs2/Shp2/Shc1, MAPK assays, lens phenotyping","pmids":["40327534"],"confidence":"High","gaps":["Quantitative contribution of each adaptor to Grb2 recruitment unresolved","Generalizability to other tissues untested"]},{"year":null,"claim":"How the lipid-raft-anchored FRS2alpha integrates the multiple competing inputs (FGFR, Trk, RET, VEGFR, EphA4) into context-specific ERK versus PI3K versus RhoA outputs, and the structural mechanism by which C-terminal autoinhibition and threonine feedback are dynamically tuned, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No full-length FRS2alpha structure in a receptor-bound signaling complex","Quantitative model of adaptor competition and feedback dynamics lacking","VEGFR and EphA4 binding modes not structurally defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,3,6,33]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,11,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,30,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,4,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,13,15,17,18]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[22,23]}],"complexes":["FRS2alpha-Grb2-Cbl complex","FRS2alpha-Grb2-Sos1-Shp2 complex","EphA4-FGFR-FRS2alpha ternary complex"],"partners":["GRB2","PTPN11","CBL","GAB1","RET","FGFR1","RND1","SRC"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8WU20","full_name":"Fibroblast growth factor receptor substrate 2","aliases":["FGFR-signaling adaptor SNT","Suc1-associated neurotrophic factor target 1","SNT-1"],"length_aa":508,"mass_kda":57.0,"function":"Adapter protein that links activated FGR and NGF receptors to downstream signaling pathways. Plays an important role in the activation of MAP kinases and in the phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, in response to ligand-mediated activation of FGFR1. Modulates signaling via SHC1 by competing for a common binding site on NTRK1","subcellular_location":"Endomembrane system","url":"https://www.uniprot.org/uniprotkb/Q8WU20/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FRS2","classification":"Not Classified","n_dependent_lines":62,"n_total_lines":1208,"dependency_fraction":0.05132450331125828},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FRS2","total_profiled":1310},"omim":[{"mim_id":"618608","title":"INTELLECTUAL DEVELOPMENTAL DISORDER WITH NASAL SPEECH, DYSMORPHIC FACIES, AND VARIABLE SKELETAL ANOMALIES; IDNADFS","url":"https://www.omim.org/entry/618608"},{"mim_id":"609436","title":"FIBROBLAST GROWTH FACTOR 21; FGF21","url":"https://www.omim.org/entry/609436"},{"mim_id":"607744","title":"FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 3; FRS3","url":"https://www.omim.org/entry/607744"},{"mim_id":"607743","title":"FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 2; FRS2","url":"https://www.omim.org/entry/607743"},{"mim_id":"606398","title":"ACTIVATING TRANSCRIPTION FACTOR 5; ATF5","url":"https://www.omim.org/entry/606398"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Plasma membrane","reliability":"Uncertain"},{"location":"Cell Junctions","reliability":"Uncertain"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FRS2"},"hgnc":{"alias_symbol":["SNT-1","FRS2alpha","SNT1","FRS2A"],"prev_symbol":[]},"alphafold":{"accession":"Q8WU20","domains":[{"cath_id":"2.30.29.30","chopping":"20-117_194-198","consensus_level":"high","plddt":88.1603,"start":20,"end":198}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WU20","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WU20-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WU20-F1-predicted_aligned_error_v6.png","plddt_mean":57.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FRS2","jax_strain_url":"https://www.jax.org/strain/search?query=FRS2"},"sequence":{"accession":"Q8WU20","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WU20.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WU20/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WU20"}},"corpus_meta":[{"pmid":"10629055","id":"PMC_10629055","title":"FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10629055","citation_count":287,"is_preprint":false},{"pmid":"9632781","id":"PMC_9632781","title":"Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9632781","citation_count":283,"is_preprint":false},{"pmid":"11447289","id":"PMC_11447289","title":"Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11447289","citation_count":253,"is_preprint":false},{"pmid":"18452557","id":"PMC_18452557","title":"Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/18452557","citation_count":203,"is_preprint":false},{"pmid":"10092678","id":"PMC_10092678","title":"The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10092678","citation_count":191,"is_preprint":false},{"pmid":"11997436","id":"PMC_11997436","title":"FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11997436","citation_count":155,"is_preprint":false},{"pmid":"12419216","id":"PMC_12419216","title":"The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors.","date":"2002","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12419216","citation_count":132,"is_preprint":false},{"pmid":"11390647","id":"PMC_11390647","title":"Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11390647","citation_count":114,"is_preprint":false},{"pmid":"16421190","id":"PMC_16421190","title":"Context-specific requirements for Fgfr1 signaling through Frs2 and Frs3 during mouse development.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16421190","citation_count":107,"is_preprint":false},{"pmid":"23393200","id":"PMC_23393200","title":"Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23393200","citation_count":87,"is_preprint":false},{"pmid":"11360177","id":"PMC_11360177","title":"Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11360177","citation_count":87,"is_preprint":false},{"pmid":"12181353","id":"PMC_12181353","title":"The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.","date":"2002","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/12181353","citation_count":76,"is_preprint":false},{"pmid":"15569927","id":"PMC_15569927","title":"Tyrosine phosphorylation sites on FRS2alpha responsible for Shp2 recruitment are critical for induction of lens and retina.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15569927","citation_count":75,"is_preprint":false},{"pmid":"22207710","id":"PMC_22207710","title":"FRS2α-mediated FGF signals suppress premature differentiation of cardiac stem cells through regulating autophagy activity.","date":"2011","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22207710","citation_count":75,"is_preprint":false},{"pmid":"15870281","id":"PMC_15870281","title":"The docking protein FRS2alpha is an essential component of multiple fibroblast growth factor responses during early mouse development.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15870281","citation_count":74,"is_preprint":false},{"pmid":"30755618","id":"PMC_30755618","title":"Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30755618","citation_count":68,"is_preprint":false},{"pmid":"24465223","id":"PMC_24465223","title":"FGFR1-Frs2/3 signalling maintains sensory progenitors during inner ear hair cell formation.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24465223","citation_count":64,"is_preprint":false},{"pmid":"15094036","id":"PMC_15094036","title":"FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15094036","citation_count":62,"is_preprint":false},{"pmid":"19103595","id":"PMC_19103595","title":"Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19103595","citation_count":60,"is_preprint":false},{"pmid":"18832393","id":"PMC_18832393","title":"Frs2alpha-deficiency in cardiac progenitors disrupts a subset of FGF signals required for outflow tract morphogenesis.","date":"2008","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18832393","citation_count":59,"is_preprint":false},{"pmid":"16239343","id":"PMC_16239343","title":"Essential role of Shp2-binding sites on FRS2alpha for corticogenesis and for FGF2-dependent proliferation of neural progenitor cells.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16239343","citation_count":59,"is_preprint":false},{"pmid":"11729184","id":"PMC_11729184","title":"Association of the signaling adaptor FRS2 with fibroblast growth factor receptor 1 (Fgfr1) is mediated by alternative splicing of the juxtamembrane domain.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11729184","citation_count":57,"is_preprint":false},{"pmid":"15564375","id":"PMC_15564375","title":"FRS2-dependent SRC activation is required for fibroblast growth factor receptor-induced phosphorylation of Sprouty and suppression of ERK activity.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15564375","citation_count":50,"is_preprint":false},{"pmid":"15738000","id":"PMC_15738000","title":"Direct interaction of Rnd1 with FRS2 beta regulates Rnd1-induced down-regulation of RhoA activity and is involved in fibroblast growth factor-induced neurite outgrowth in PC12 cells.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15738000","citation_count":48,"is_preprint":false},{"pmid":"19890878","id":"PMC_19890878","title":"An FGF4-FRS2alpha-Cdx2 axis in trophoblast stem cells induces Bmp4 to regulate proper growth of early mouse embryos.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/19890878","citation_count":46,"is_preprint":false},{"pmid":"12571252","id":"PMC_12571252","title":"Fibroblast growth factor-2-induced signaling through lipid raft-associated fibroblast growth factor receptor substrate 2 (FRS2).","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12571252","citation_count":46,"is_preprint":false},{"pmid":"30001240","id":"PMC_30001240","title":"Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.","date":"2018","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30001240","citation_count":40,"is_preprint":false},{"pmid":"32141564","id":"PMC_32141564","title":"LncRNA ANRIL regulates cell proliferation and migration via sponging miR-339-5p and regulating FRS2 expression in atherosclerosis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32141564","citation_count":39,"is_preprint":false},{"pmid":"12974390","id":"PMC_12974390","title":"EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2.","date":"2003","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12974390","citation_count":37,"is_preprint":false},{"pmid":"26969380","id":"PMC_26969380","title":"Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating FGFR4/FRS2α-ERK1/2 pathway-mediated NF-κB activation.","date":"2016","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26969380","citation_count":37,"is_preprint":false},{"pmid":"17868091","id":"PMC_17868091","title":"Generation of an Frs2alpha conditional null allele.","date":"2007","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/17868091","citation_count":35,"is_preprint":false},{"pmid":"21927580","id":"PMC_21927580","title":"FRS2α is essential for the fibroblast growth factor to regulate the mTOR pathway and autophagy in mouse embryonic fibroblasts.","date":"2011","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21927580","citation_count":35,"is_preprint":false},{"pmid":"11335123","id":"PMC_11335123","title":"Developmental expression patterns of the signaling adapters FRS-2 and FRS-3 during early embryogenesis.","date":"2001","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11335123","citation_count":34,"is_preprint":false},{"pmid":"19456272","id":"PMC_19456272","title":"The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment.","date":"2009","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/19456272","citation_count":32,"is_preprint":false},{"pmid":"17145761","id":"PMC_17145761","title":"Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17145761","citation_count":32,"is_preprint":false},{"pmid":"16476447","id":"PMC_16476447","title":"K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16476447","citation_count":32,"is_preprint":false},{"pmid":"25368431","id":"PMC_25368431","title":"The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25368431","citation_count":31,"is_preprint":false},{"pmid":"17274988","id":"PMC_17274988","title":"ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation.","date":"2007","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17274988","citation_count":31,"is_preprint":false},{"pmid":"19235715","id":"PMC_19235715","title":"FRS2alpha is required for the separation, migration, and survival of pharyngeal-endoderm derived organs including thyroid, ultimobranchial body, parathyroid, and thymus.","date":"2009","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/19235715","citation_count":31,"is_preprint":false},{"pmid":"10383403","id":"PMC_10383403","title":"Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10383403","citation_count":31,"is_preprint":false},{"pmid":"23136392","id":"PMC_23136392","title":"Frs2α enhances fibroblast growth factor-mediated survival and differentiation in lens development.","date":"2012","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23136392","citation_count":30,"is_preprint":false},{"pmid":"20652960","id":"PMC_20652960","title":"FRS2α regulates Erk levels to control a self-renewal target Hes1 and proliferation of FGF-responsive neural stem/progenitor cells.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/20652960","citation_count":30,"is_preprint":false},{"pmid":"19741018","id":"PMC_19741018","title":"Deletion of Frs2alpha from the ureteric epithelium causes renal hypoplasia.","date":"2009","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19741018","citation_count":28,"is_preprint":false},{"pmid":"21350013","id":"PMC_21350013","title":"Independent roles of Fgfr2 and Frs2alpha in ureteric epithelium.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21350013","citation_count":26,"is_preprint":false},{"pmid":"17901128","id":"PMC_17901128","title":"Fibroblast growth factor receptor 1 (FGFR1) tyrosine phosphorylation regulates binding of FGFR substrate 2alpha (FRS2alpha) but not FRS2 to the receptor.","date":"2007","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/17901128","citation_count":25,"is_preprint":false},{"pmid":"11877385","id":"PMC_11877385","title":"FRS2 PTB domain conformation regulates interactions with divergent neurotrophic receptors.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11877385","citation_count":25,"is_preprint":false},{"pmid":"18177855","id":"PMC_18177855","title":"FRS2 alpha 2F/2F mice lack carotid body and exhibit abnormalities of the superior cervical sympathetic ganglion and carotid sinus nerve.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18177855","citation_count":25,"is_preprint":false},{"pmid":"22282599","id":"PMC_22282599","title":"Ureteric morphogenesis requires Fgfr1 and Fgfr2/Frs2α signaling in the metanephric mesenchyme.","date":"2012","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/22282599","citation_count":24,"is_preprint":false},{"pmid":"33761622","id":"PMC_33761622","title":"Kaempferol alleviates human endothelial cell injury through circNOL12/miR-6873-3p/FRS2 axis.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33761622","citation_count":24,"is_preprint":false},{"pmid":"29540482","id":"PMC_29540482","title":"Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29540482","citation_count":23,"is_preprint":false},{"pmid":"31194576","id":"PMC_31194576","title":"miR-200c-3p Suppresses the Proliferative, Migratory, and Invasive Capacities of Nephroblastoma Cells via Targeting FRS2.","date":"2019","source":"Biopreservation and biobanking","url":"https://pubmed.ncbi.nlm.nih.gov/31194576","citation_count":22,"is_preprint":false},{"pmid":"11463744","id":"PMC_11463744","title":"Xenopus FRS2 is involved in early embryogenesis in cooperation with the Src family kinase Laloo.","date":"2001","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/11463744","citation_count":22,"is_preprint":false},{"pmid":"32515146","id":"PMC_32515146","title":"Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR-1271-5p and upregulating FRS2.","date":"2020","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32515146","citation_count":20,"is_preprint":false},{"pmid":"25641696","id":"PMC_25641696","title":"Fibroblast growth factor receptor-Frs2α signaling is critical for nephron progenitors.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25641696","citation_count":19,"is_preprint":false},{"pmid":"22078327","id":"PMC_22078327","title":"Role and expression of FRS2 and FRS3 in prostate cancer.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22078327","citation_count":19,"is_preprint":false},{"pmid":"34159479","id":"PMC_34159479","title":"Circular RNA circUBR4 regulates ox-LDL-induced proliferation and migration of vascular smooth muscle cells through miR-185-5p/FRS2 axis.","date":"2021","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34159479","citation_count":19,"is_preprint":false},{"pmid":"28829507","id":"PMC_28829507","title":"MicroRNA-613 attenuates the proliferation, migration and invasion of Wilms' tumor via targeting FRS2.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28829507","citation_count":18,"is_preprint":false},{"pmid":"23782834","id":"PMC_23782834","title":"The Role of fibroblast growth factor receptor substrate 2 (FRS2) in the regulation of two activity levels of the components of the extracellular signal-regulated kinase (ERK) pathway in the mouse epididymis.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23782834","citation_count":18,"is_preprint":false},{"pmid":"25900027","id":"PMC_25900027","title":"The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25900027","citation_count":17,"is_preprint":false},{"pmid":"24706887","id":"PMC_24706887","title":"The docking protein FRS2α is a critical regulator of VEGF receptors signaling.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24706887","citation_count":16,"is_preprint":false},{"pmid":"16682955","id":"PMC_16682955","title":"Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16682955","citation_count":16,"is_preprint":false},{"pmid":"20184660","id":"PMC_20184660","title":"Ternary complex formation of EphA4, FGFR and FRS2α plays an important role in the proliferation of embryonic neural stem/progenitor cells.","date":"2010","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/20184660","citation_count":16,"is_preprint":false},{"pmid":"30795553","id":"PMC_30795553","title":"Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30795553","citation_count":16,"is_preprint":false},{"pmid":"31957822","id":"PMC_31957822","title":"MiR-140-5p and miR-92a-3p suppress the cell proliferation, migration and invasion and promoted apoptosis in Wilms' tumor by targeting FRS2.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31957822","citation_count":15,"is_preprint":false},{"pmid":"10650943","id":"PMC_10650943","title":"Potential involvement of FRS2 in insulin signaling.","date":"2000","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10650943","citation_count":15,"is_preprint":false},{"pmid":"11731233","id":"PMC_11731233","title":"SNT-1/FRS2alpha physically interacts with Laloo and mediates mesoderm induction by fibroblast growth factor.","date":"2001","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11731233","citation_count":14,"is_preprint":false},{"pmid":"25056539","id":"PMC_25056539","title":"Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity.","date":"2014","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25056539","citation_count":14,"is_preprint":false},{"pmid":"12082104","id":"PMC_12082104","title":"SNT1/FRS2 mediates germinal vesicle breakdown induced by an activated FGF receptor1 in Xenopus oocytes.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12082104","citation_count":14,"is_preprint":false},{"pmid":"20803545","id":"PMC_20803545","title":"FGF2 promotes Msx2 stimulated PC-1 expression via Frs2/MAPK signaling.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20803545","citation_count":13,"is_preprint":false},{"pmid":"25159185","id":"PMC_25159185","title":"The signaling adapter, FRS2, facilitates neuronal branching in primary cortical neurons via both Grb2- and Shp2-dependent mechanisms.","date":"2014","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/25159185","citation_count":13,"is_preprint":false},{"pmid":"30131252","id":"PMC_30131252","title":"Intraocular miR-211 exacerbates pressure-induced cell death in retinal ganglion cells via direct repression of FRS2 signaling.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30131252","citation_count":13,"is_preprint":false},{"pmid":"31788020","id":"PMC_31788020","title":"FGF-induced LHX9 regulates the progression and metastasis of osteosarcoma via FRS2/TGF-β/β-catenin pathway.","date":"2019","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/31788020","citation_count":12,"is_preprint":false},{"pmid":"24470253","id":"PMC_24470253","title":"Structural insights into FRS2α PTB domain recognition by neurotrophin receptor TrkB.","date":"2014","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/24470253","citation_count":11,"is_preprint":false},{"pmid":"33481659","id":"PMC_33481659","title":"LncRNA SNHG6 Promotes Wilms' Tumor Progression Through Regulating miR-429/FRS2 Axis.","date":"2021","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/33481659","citation_count":11,"is_preprint":false},{"pmid":"34882114","id":"PMC_34882114","title":"Circ_0002984 Enhances Growth, Invasion, and Migration in PDGF-bb-Induced Vascular Smooth Muscle Cells Through miR-379-5p/FRS2 Axis.","date":"2021","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34882114","citation_count":11,"is_preprint":false},{"pmid":"10748122","id":"PMC_10748122","title":"A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10748122","citation_count":11,"is_preprint":false},{"pmid":"31184863","id":"PMC_31184863","title":"Myristoylation-Dependent Palmitoylation of the Receptor Tyrosine Kinase Adaptor FRS2α.","date":"2019","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31184863","citation_count":10,"is_preprint":false},{"pmid":"36495366","id":"PMC_36495366","title":"Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/36495366","citation_count":10,"is_preprint":false},{"pmid":"34414852","id":"PMC_34414852","title":"Long non-coding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) regulates fibroblast growth factor receptor substrate 2 (FRS2) by targeting microRNA (miR)-29-3p in hypertrophic scar fibroblasts.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34414852","citation_count":10,"is_preprint":false},{"pmid":"20308281","id":"PMC_20308281","title":"Caenorhabditis elegans fibroblast growth factor receptor signaling can occur independently of the multi-substrate adaptor FRS2.","date":"2010","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20308281","citation_count":10,"is_preprint":false},{"pmid":"2336390","id":"PMC_2336390","title":"Construction of a FRS1-FRS2 operon encoding the structural genes for the alpha and beta subunits of yeast phenylalanyl-tRNA synthetase and its use in deletion analysis.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2336390","citation_count":10,"is_preprint":false},{"pmid":"12688531","id":"PMC_12688531","title":"Genomic organization and comparative sequence analysis of the mouse and human FRS2, FRS3 genes.","date":"2003","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/12688531","citation_count":9,"is_preprint":false},{"pmid":"26024354","id":"PMC_26024354","title":"Trans-Activation between EphA and FGFR Regulates Self-Renewal and Differentiation of Mouse Embryonic Neural Stem/Progenitor Cells via Differential Activation of FRS2α.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26024354","citation_count":8,"is_preprint":false},{"pmid":"12065641","id":"PMC_12065641","title":"Overexpression of the signaling adapter FRS2 reconstitutes the cell cycle deficit of a nerve growth factor non-responsive TrkA receptor mutant.","date":"2002","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12065641","citation_count":8,"is_preprint":false},{"pmid":"28895643","id":"PMC_28895643","title":"Thyroid Hormone-Induced Expression of the Hepatic Scaffold Proteins Sestrin2, β-Klotho, and FRS2α in Relation to FGF21-AMPK Signaling.","date":"2017","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/28895643","citation_count":7,"is_preprint":false},{"pmid":"32578051","id":"PMC_32578051","title":"MiR-96 promotes apoptosis of nucleus pulpous cells by targeting FRS2.","date":"2020","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/32578051","citation_count":7,"is_preprint":false},{"pmid":"37595815","id":"PMC_37595815","title":"Effective fraction of Gualou-Xiebai-Banxia decoction inhibits the apoptosis of myocardial cells induced by ox-LDL via FGF21/FGFR1/βKlotho-FRS2α signal pathway.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37595815","citation_count":6,"is_preprint":false},{"pmid":"34696768","id":"PMC_34696768","title":"Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.","date":"2021","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34696768","citation_count":5,"is_preprint":false},{"pmid":"38159618","id":"PMC_38159618","title":"FRS2 regulated by miR-429 and miR-206 promotes angiogenesis in osteosarcoma.","date":"2023","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/38159618","citation_count":4,"is_preprint":false},{"pmid":"31669335","id":"PMC_31669335","title":"FRS2α-dependent cell fate transition during endocardial cushion morphogenesis.","date":"2019","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31669335","citation_count":4,"is_preprint":false},{"pmid":"37264620","id":"PMC_37264620","title":"Over-expression of microRNA-145 Elevating Autophagy Activities via Downregulating FRS2 Expression.","date":"2024","source":"Combinatorial chemistry & high throughput screening","url":"https://pubmed.ncbi.nlm.nih.gov/37264620","citation_count":4,"is_preprint":false},{"pmid":"29155277","id":"PMC_29155277","title":"Neurotrophin and FGF Signaling Adapter Proteins, FRS2 and FRS3, Regulate Dentate Granule Cell Maturation and Excitatory Synaptogenesis.","date":"2017","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29155277","citation_count":4,"is_preprint":false},{"pmid":"18189271","id":"PMC_18189271","title":"Cell migration by a FRS2-adaptor dependent membrane relocation of ret receptors.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18189271","citation_count":4,"is_preprint":false},{"pmid":"37421147","id":"PMC_37421147","title":"FRS2-independent GRB2 interaction with FGFR2 is not required for embryonic development.","date":"2023","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/37421147","citation_count":3,"is_preprint":false},{"pmid":"40327534","id":"PMC_40327534","title":"Shc1 cooperates with Frs2 and Shp2 to recruit Grb2 in FGF-induced lens development.","date":"2025","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/40327534","citation_count":2,"is_preprint":false},{"pmid":"37458641","id":"PMC_37458641","title":"Expression of fibroblast growth factor receptor substrate 2 (FRS2) in primary retroperitoneal liposarcoma and its clinical implications.","date":"2023","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37458641","citation_count":2,"is_preprint":false},{"pmid":"37543351","id":"PMC_37543351","title":"Characterization of the folding and binding properties of the PTB domain of FRS2 with phosphorylated and unphosphorylated ligands.","date":"2023","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/37543351","citation_count":2,"is_preprint":false},{"pmid":"38376663","id":"PMC_38376663","title":"Circ_0004872 deficiency attenuates ox-LDL-induced vascular smooth muscle cell dysfunction by miR-424-5p-dependent regulation of FRS2.","date":"2024","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38376663","citation_count":2,"is_preprint":false},{"pmid":"36387361","id":"PMC_36387361","title":"TRIM44 Promotes Endometrial Carcinoma Progression by Activating the FRS2 Signalling Pathway.","date":"2022","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/36387361","citation_count":2,"is_preprint":false},{"pmid":"38328402","id":"PMC_38328402","title":"miR-338-3p acts as a tumor suppressor in lung squamous cell carcinoma by targeting FGFR2/FRS2.","date":"2022","source":"Cancer pathogenesis and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38328402","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53474,"output_tokens":10235,"usd":0.156973,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20638,"output_tokens":8350,"usd":0.15597,"stage2_stop_reason":"end_turn"},"total_usd":0.312943,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"FRS2 (FRS2alpha) forms a complex with the N-terminal SH2 domain of Shp2 upon FGF stimulation; the complex also contains Grb2 and Sos1. An FRS2 mutant deficient in both Grb2 and Shp2 binding fails to sustain MAP kinase activation and cannot induce PC12 cell differentiation in response to FGF. Shp2 catalytic activity is required for sustained ERK activation and potentiation of FGF-induced differentiation.\",\n      \"method\": \"Co-immunoprecipitation, point mutagenesis of FRS2, dominant-negative Shp2 expression, PC12 differentiation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP combined with functional mutagenesis and cell differentiation readout; replicated across multiple mutant constructs in a single rigorous study\",\n      \"pmids\": [\"9632781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The PTB domains of FRS2alpha and FRS2beta bind directly to a highly conserved juxtamembrane sequence in FGFR1 constitutively (phosphorylation-independent), while binding to TrkA (NGF receptor) at pY490 (NPXpY motif) is phosphorylation-dependent. Thus the same PTB domain recognizes two structurally distinct receptor sequences by different mechanisms. FRS2alpha tyrosine phosphorylation in response to NGF is diminished when a kinase-inactive FGFR1 is overexpressed, indicating FGFR1 can sequester FRS2 away from TrkA.\",\n      \"method\": \"Peptide competition assays, deletion and alanine-scanning mutagenesis, phosphorylation-dependent binding assays, dominant-negative FGFR1 overexpression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro binding assays with mutagenesis and peptide competition; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"10629055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"FRS2 PTB domain binds TrkA at the same phosphotyrosine residue (Y490) as Shc, suggesting competitive binding. FRS2 also binds Grb2, Crk, SH-PTP-2, p13(suc1), and the SH3 domain of Src. Overexpression of FRS2 in cells expressing a TrkA NGF-nonresponsive mutant reconstitutes NGF-induced cell cycle arrest and neuronal differentiation.\",\n      \"method\": \"cDNA cloning, co-immunoprecipitation, functional reconstitution by overexpression in mutant TrkA cells, differentiation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple binding partners identified by Co-IP, functional rescue by overexpression, replicated conceptually across multiple constructs\",\n      \"pmids\": [\"10092678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Targeted disruption of FRS2alpha in mice causes embryonic lethality at E7.0–E7.5. FRS2alpha-deficient fibroblasts show impaired FGF-induced MAP kinase stimulation, PI3K activation, chemotaxis, and cell proliferation. Tyrosine-phosphorylated FRS2alpha assembles a multiprotein complex including Gab1. Different tyrosine phosphorylation sites on FRS2alpha mediate distinct FGF-induced biological responses.\",\n      \"method\": \"Gene knockout (homologous recombination), MEF functional assays (MAPK, PI3K, chemotaxis, proliferation), multiprotein complex assembly analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with multiple orthogonal functional readouts, embryonic lethality phenotype confirms central signaling role\",\n      \"pmids\": [\"11447289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The FRS2 PTB domain binds RET at pY1062, the same residue that binds Shc. FRS2-RET binding is ligand-dependent for normal RET but constitutive for oncogenic RET-PTC forms, leading to constitutive FRS2 tyrosine phosphorylation and sustained MAP kinase activation. HSCR-associated loss-of-function RET mutants show impaired FRS2 binding and reduced MAP kinase activation.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis of RET (Y1062), cell proliferation and MAP kinase assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with mutagenesis, multiple oncogenic and loss-of-function mutants tested, functional MAPK readouts\",\n      \"pmids\": [\"11390647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The FRS2 docking site on RET is pY1062; SNT/FRS2 is associated with GRB2 but not GAB1 upon RET activation (unlike Shc which associates with both GRB2 and GAB1), indicating FRS2 selectively activates RAS/MAPK but not PI3K/AKT downstream of RET.\",\n      \"method\": \"Site-directed mutagenesis of RET, co-immunoprecipitation, comparison of Shc vs FRS2 complexes\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with mutagenesis, single lab, consistent with PMID:11390647\",\n      \"pmids\": [\"11360177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Grb2 bound to tyrosine-phosphorylated FRS2alpha recruits the E3 ubiquitin ligase Cbl through Grb2's SH3 domains, forming a ternary FRS2alpha–Grb2–Cbl complex that ubiquitinates FGFR and FRS2alpha in response to FGF, thereby attenuating FGF receptor signaling. FRS2alpha-null cells show only partial impairment of receptor downregulation, indicating redundant mechanisms.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, FRS2alpha-null cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP of ternary complex with functional ubiquitination readout, knockout validation\",\n      \"pmids\": [\"11997436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FRS2alpha is phosphorylated by MAP kinase on multiple threonine residues upon FGF stimulation (and also by insulin, EGF, PDGF without FRS2alpha tyrosine phosphorylation). Preventing FRS2alpha threonine phosphorylation results in constitutive tyrosine phosphorylation, enhanced ERK activation, cell migration, proliferation, and anchorage-independent growth, revealing a MAPK-mediated negative feedback loop controlling FRS2alpha activity.\",\n      \"method\": \"Threonine phosphorylation site mutagenesis, in vitro kinase assays, soft-agar colony formation, cell proliferation and migration assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis combined with multiple functional cellular readouts including anchorage-independent growth\",\n      \"pmids\": [\"12419216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Alternative splicing of the FGFR1 juxtamembrane region (inclusion of VT motif) is required for FRS2 interaction with FGFR1; VT-minus isoforms cannot bind FRS2, accounting for their inability to activate ERK2.\",\n      \"method\": \"Co-immunoprecipitation with VT+ and VT- isoforms, ERK2 phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with splice isoforms plus functional ERK readout, single lab\",\n      \"pmids\": [\"11729184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The FRS2alpha PTB domain uses thermodynamically distinct binding modes for TrkA/TrkB (enthalpy-driven, phosphotyrosine-dependent NPXpY recognition) versus FGFR1 (entropy-driven, phosphorylation-independent). NMR analysis shows the unstructured region C-terminal to the PTB domain alters PTB conformation and binding; disruption of the beta8-strand weakens FGFR interaction.\",\n      \"method\": \"Isothermal titration calorimetry, NMR spectroscopy, mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biophysical characterization (ITC + NMR) with mutagenesis, multiple orthogonal methods\",\n      \"pmids\": [\"11877385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FRS2 is localized exclusively to lipid raft membrane microdomains in vitro and in vivo. Serine/threonine phosphorylation of FRS2 within lipid rafts (mediated by PKC, Src family kinases, MEK1/2) indirectly reduces FRS2 tyrosine phosphorylation levels. Grb2 is recruited to lipid rafts during FGF2 signaling.\",\n      \"method\": \"Lipid raft fractionation, phosphorylation assays, inhibitor studies (PKC, Src, MEK), Grb2 co-fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation with functional inhibitor studies, single lab\",\n      \"pmids\": [\"12571252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FRS2 undergoes ERK1/2-mediated serine/threonine phosphorylation in response to EGF and FGF stimulation. ERK1/2 constitutively associates with the central portion of FRS2, while the C-terminal region is the ERK2 substrate. Inhibiting ERK1/2 enhances FRS2 tyrosine phosphorylation, demonstrating a negative feedback loop where activated ERK1/2 phosphorylates FRS2 to downregulate its tyrosine phosphorylation.\",\n      \"method\": \"MEK inhibitor (U0126), co-immunoprecipitation of ERK with FRS2, in vitro kinase assays, SDS-PAGE mobility shift\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay and Co-IP with functional inhibitor readout, single lab, consistent with PMID:12419216\",\n      \"pmids\": [\"12974390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FGF receptor-mediated Sprouty2 phosphorylation on Y55 requires FRS2 as an intermediary; FRS2 recruits and activates Src family kinases, which then directly phosphorylate Sprouty2. Phospho-Sprouty2 forms a complex with Src and inhibits ERK pathway activation.\",\n      \"method\": \"Src inhibitor, mutant cell lines, co-immunoprecipitation of Src–Sprouty2 complex, FRS2-dependent Src activation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition and mutant cells with multiple functional readouts, single lab\",\n      \"pmids\": [\"15564375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Shp2-binding tyrosine sites on FRS2alpha are critical for retinal and lens induction in vivo: Frs2alpha(2F/2F) mice (Shp2-binding sites mutated) develop anophthalmia/microphthalmia with reduced pERK and decreased Pax6, Six3, Chx10 and Bmp4 expression, while Frs2alpha(4F/4F) (Grb2-binding sites mutated) mice show normal early eye development.\",\n      \"method\": \"Knock-in point mutation mice, immunohistochemistry, in vivo ERK activation measurement, marker gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with multiple molecular and phenotypic readouts, clean comparison of two distinct mutant alleles\",\n      \"pmids\": [\"15569927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FRS2alpha directly associates with Rnd1 (and FRS2beta does as well); FRS2beta interaction with Rnd1 suppresses Rnd1's inhibitory effect on RhoA. Upon FGFR1 activation and FRS2beta tyrosine phosphorylation, Shp2 is recruited to FRS2beta and displaces Rnd1; liberated Rnd1 then inhibits RhoA activity to promote neurite outgrowth.\",\n      \"method\": \"Direct protein binding (pulldown/Co-IP), FGFR1 phosphorylation assays, RhoA activity assays, siRNA knockdown of Rnd1, neurite outgrowth assay in PC12 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding plus RhoA functional assay plus siRNA knockdown, single lab\",\n      \"pmids\": [\"15738000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Disruption of Shp2-binding sites on FRS2alpha (Frs2alpha(2F)) in mice causes severe cortical development defects due to loss of intermediate progenitor cells. FRS2alpha is essential for FGF2-responsive neural progenitor cell proliferation but not for self-renewal capacity after FGF2 stimulation.\",\n      \"method\": \"Knock-in point mutation mice, BrdU labeling, neurosphere assay, histological analysis of cortex\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knock-in with multiple cellular and molecular readouts\",\n      \"pmids\": [\"16239343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"FRS2 associates with atypical protein kinase C lambda (PKClambda) in Swiss 3T3 cells stimulated with bFGF; PKC zeta also binds FRS2. The interaction is likely direct (yeast two-hybrid). Activated PKClambda (constitutively active A120E mutant) shows greater than 2-fold higher FRS2 binding than wild-type. In vitro kinase assays show FRS2 is not a substrate for PKClambda or PKCzeta, suggesting FRS2 acts as an anchoring/targeting protein for activated atypical PKCs at the plasma membrane.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid, in vitro kinase assay, constitutively active PKClambda mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus in vitro kinase assay, single lab\",\n      \"pmids\": [\"10383403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FRS2alpha is required for separation, migration, and survival of pharyngeal-endoderm-derived organs (thyroid, ultimobranchial body, parathyroid, thymus) in Frs2alpha(2F/2F) mice; organ-specific differentiation markers are initially expressed normally, indicating FRS2alpha mediates migration but not initial specification of these organs.\",\n      \"method\": \"Knock-in point mutation mice (Shp2-binding site), histology, immunostaining for differentiation markers at sequential developmental stages\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model with multiple marker analyses and temporal staging, single lab\",\n      \"pmids\": [\"19235715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FRS2alpha ablation in mesodermal outflow tract progenitors (second heart field) impairs their expansion, causing outflow tract misalignment/hypoplasia, and also causes defective endothelial-to-mesenchymal transition and impaired neural crest recruitment, resulting in outflow tract septation defects.\",\n      \"method\": \"Conditional knockout using Cre/loxP, histology, lineage tracing, immunostaining\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific knockout with multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"18832393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FRS2alpha loss-of-function FGFR2 IIIb C3 variant (Y770F mutation) causes persistent FRS2 binding to FGFR2 IIIb, enhanced FRS2 tyrosine phosphorylation, and increased transforming activity. FRS2 binding to FGFR2 IIIb is required for Y770F-mediated enhanced transformation, establishing that persistent FRS2 engagement drives oncogenic signaling.\",\n      \"method\": \"Site-directed mutagenesis of FGFR2 (Y770F, L773A), Co-IP of FRS2–FGFR2 complex, focus formation/transformation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis combined with functional transformation assays and Co-IP, single lab\",\n      \"pmids\": [\"19103595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"EphA4 directly interacts with the FRS2alpha PTB domain upon phosphorylation of the EphA4 juxtamembrane domain; EphA4 directly phosphorylates FRS2alpha in vitro. A ternary complex of EphA4, FGFR, and FRS2alpha forms, with FRS2alpha and EphA4 binding to different regions of the FGFR juxtamembrane domain simultaneously. Dominant-negative EphA4 or truncated FRS2alpha lacking tyrosine phosphorylation sites inhibit ligand-dependent proliferation of embryonic neural stem/progenitor cells.\",\n      \"method\": \"Yeast two-hybrid, in vitro binding assay, in vitro kinase assay, dominant-negative constructs, neural stem cell proliferation assay\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding and kinase assays with functional cellular readout, single lab\",\n      \"pmids\": [\"20184660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FRS2alpha mediates FGF4-induced ERK activation in trophoblast stem cells to enhance Cdx2 expression; Cdx2 binds an FGF4-responsive enhancer in the Bmp4 promoter, driving Bmp4 production. Exogenous Bmp4 rescues defective growth of Frs2alpha-null inner cell mass, establishing a paracrine FRS2alpha–ERK–Cdx2–Bmp4 axis.\",\n      \"method\": \"Frs2alpha-null ES/TS cell culture, ChIP for Cdx2 on Bmp4 promoter, Bmp4 rescue experiment, ERK phosphorylation assays\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus genetic rescue plus signaling assays, single lab\",\n      \"pmids\": [\"19890878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FRS2alpha-mediated FGF signaling suppresses autophagy through the PI3K/Akt/mTOR pathway in mouse embryonic fibroblasts. Loss of FRS2alpha increases autophagy and promotes premature differentiation of cardiac progenitor cells.\",\n      \"method\": \"Frs2alpha conditional knockout in heart progenitors, embryoid body culture, autophagy markers (LC3), PI3K/Akt/mTOR inhibitor studies in Frs2alpha-null MEFs\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with pharmacological pathway dissection and multiple cellular readouts, single lab\",\n      \"pmids\": [\"22207710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FRS2alpha-mediated FGF signaling activates mTOR via PI3K/Akt and suppresses autophagy in MEFs; the PI3K/Akt–mTOR axis is the downstream mediator of FGF's autophagy suppression.\",\n      \"method\": \"Frs2alpha-null MEFs, PI3K/Akt/mTOR inhibitor studies, autophagy marker assays (LC3 conversion)\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null cells with pharmacological pathway inhibition, single lab\",\n      \"pmids\": [\"21927580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Xenopus FRS2 (xFRS2) is tyrosine-phosphorylated in early embryos; overexpression of unphosphorylatable xFRS2 interferes with FGF-dependent mesoderm formation. Src family kinase Laloo binds xFRS2, promotes its tyrosine phosphorylation, and both associate with Xenopus FGFR1, placing FRS2 in a Laloo–FGFR1 signaling complex required for mesoderm induction.\",\n      \"method\": \"Xenopus overexpression/dominant-negative experiments, Co-immunoprecipitation of xFRS2 with Laloo and FGFR1, tyrosine phosphorylation assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with dominant-negative functional readout in Xenopus embryo, single lab\",\n      \"pmids\": [\"11463744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Xenopus SNT-1/FRS2alpha induces mesoderm in ectodermal explants, synergizes with FGF, and requires Ras activity; dominant-inhibitory SNT-1 blocks FGF-mediated mesoderm induction and disrupts axis formation in vivo. SNT-1 physically associates with Src-like kinase Laloo, and SNT-1 activity is required for Laloo-induced mesoderm induction.\",\n      \"method\": \"Xenopus embryo explant assay, dominant-negative constructs, co-immunoprecipitation, Ras inhibition\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional epistasis in Xenopus embryo with Co-IP, single lab, consistent with PMID:11463744\",\n      \"pmids\": [\"11731233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Xenopus FRS2 (XFRS2) is essential for FGF receptor-induced oocyte maturation (germinal vesicle breakdown). Co-expression of activated XFGFR1 and XFRS2 requires MEK activity (not needed for progesterone-induced GVBD) and PI3K activity for H1 kinase activation at metaphase II. Sprouty2 acts upstream of or parallel to Raf (downstream of Ras) to inhibit XFGFR1/XFRS2-induced MAPK activation and GVBD.\",\n      \"method\": \"Xenopus oocyte microinjection, dominant-negative kinase suppressor of Ras, PI3K inhibitor (LY294002), GVBD and H1 kinase assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic/pharmacological epistasis in oocyte system with biochemical readouts, single lab\",\n      \"pmids\": [\"12082104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FRS2 selectively recruits RET to focal complexes/membrane foci, activating Src family kinases and FAK to drive cell migration. Competitive recruitment of FRS2 vs. other adaptors to Y1062 in RET determines migration outcome; Src activation requires direct interaction at Y981, and both Y1062 (FRS2) and Y981 (Src) signals act in concert to regulate migration.\",\n      \"method\": \"Co-immunoprecipitation, focal complex localization by microscopy, Src/FAK activation assays, RET mutagenesis (Y1062, Y981)\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with mutagenesis and subcellular localization readout, functional migration assay, single lab\",\n      \"pmids\": [\"18189271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FRS2alpha plays a critical role in VEGF receptor signaling: in vitro, FRS2alpha regulates VEGF-A and VEGF-C-dependent ERK activation and endothelial cell migration/proliferation; in vivo, endothelial-specific deletion of FRS2alpha profoundly impairs postnatal vascular development, angiogenesis, lymphangiogenesis, and arteriogenesis.\",\n      \"method\": \"Endothelial-specific conditional knockout (Cre/loxP), in vitro VEGF signaling assays, in vivo angiogenesis/lymphangiogenesis phenotyping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific knockout with multiple in vitro and in vivo readouts across vascular, lymphatic and arterial systems\",\n      \"pmids\": [\"24706887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The FRS2alpha PTB domain has two adjacent but distinct binding pockets: one for the non-phosphorylated FGFR juxtamembrane region and one for phosphorylated TrkA/TrkB (NPXpY), enabling mutually exclusive interaction with each receptor class. NMR structure of FRS2alpha PTB bound to phosphorylated TrkB is reported.\",\n      \"method\": \"NMR structure determination, binding pocket analysis\",\n      \"journal\": \"Proteins\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with functional validation of two binding pockets; single lab but structural data\",\n      \"pmids\": [\"24470253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FRS2alpha is N-myristoylated and also palmitoylated at cysteines 4 and 5. Mutation of C4/C5 impairs plasma membrane localization. Abolishing myristoylation (G2A mutation) also abrogates palmitoylation, indicating coupled myristoylation-dependent palmitoylation; signaling defects of the G2A mutant may thus be due to loss of palmitoylation rather than myristoylation alone.\",\n      \"method\": \"Palmitoylation assays, site-directed mutagenesis (C4A/C5A, G2A), fluorescence fluctuation spectroscopy (plasma membrane localization quantification)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical palmitoylation assay with mutagenesis and quantitative fluorescence microscopy, single lab\",\n      \"pmids\": [\"31184863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of FRS2alpha myristoylation (using N-myristoyltransferase inhibitor B13) suppresses FGF/FGFR-mediated oncogenic signaling, inhibits FGF10-induced tumorigenesis, and reduces PI3K/MAPK signaling downstream of both wild-type and drug-resistant FGFR mutants. B13 inhibits FRS2alpha phosphorylation and mildly alters its plasma membrane localization.\",\n      \"method\": \"N-myristoyltransferase inhibitor (B13), FRS2alpha phosphorylation assays, xenograft tumor model, cell proliferation/migration assays, combination with FGFR inhibitor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with in vitro and in vivo tumor readouts, single lab\",\n      \"pmids\": [\"29540482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FGFR1 tyrosine autophosphorylation is required for optimal binding to full-length FRS2alpha but not to FRS2beta; the PTB domain of FRS2alpha alone binds FGFR1 constitutively, indicating the C-terminal region of FRS2alpha inhibits PTB–FGFR1 interaction that is relieved by receptor kinase activation. The Grb2-binding sites of FRS2alpha are essential for mediating FGFR1 signals to activate the FiRE enhancer.\",\n      \"method\": \"Co-immunoprecipitation in mammalian cells with recombinant proteins, FGFR1 kinase-dead and tyrosine substitution mutants, PTB domain truncation constructs, FiRE enhancer reporter assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with multiple receptor and adaptor mutants plus reporter assay, single lab\",\n      \"pmids\": [\"17901128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FRS2 promotes neurotrophin-induced neurite outgrowth and branching in primary cortical neurons via both Grb2- and Shp2-dependent pathways. FRS2 binds Gab1 and Gab2 through Grb2, providing an indirect route to PI3K and Shp2. Loss of Shp2 binding reduces BDNF-induced MAPK activation; loss of either Grb2 or Shp2 binding impairs neuronal growth. FRS3 overexpression does not stimulate neuronal growth.\",\n      \"method\": \"Recombinant adenovirus overexpression of FRS2 mutants, primary cortical neuron culture, neurite outgrowth quantification, Co-IP of Gab1/Gab2 complexes\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional mutant FRS2 constructs in primary neurons with Co-IP evidence, single lab\",\n      \"pmids\": [\"25159185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FRS2α deletion in endothelial cells induces endothelial-to-mesenchymal transition (EndMT) by activating TGFβ signaling in a miRNA let-7-dependent manner in adult endothelium; during embryonic AV cushion morphogenesis early Frs2α deletion impairs EndMT in AV cushions, while late deletion (E10.5) has no effect, identifying FRS2α as a developmental stage-specific controller of cell fate transition.\",\n      \"method\": \"Inducible endothelial-specific conditional knockout (FRS2αiECKO at E7.5 vs E10.5), histological and molecular analysis of AV valves\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible conditional knockout with temporal staging, single lab\",\n      \"pmids\": [\"31669335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"FRS2 is phosphorylated by the insulin receptor (IR) in vitro using purified IR; insulin stimulates tyrosine phosphorylation of endogenous FRS2 in PC12/IR cells and promotes FRS2–Shp2 complex formation. FRS2 was isolated as a potential IR substrate by yeast two-hybrid screening with the Shp2 SH2 domain dependent on active IR.\",\n      \"method\": \"Yeast two-hybrid (Shp2 SH2 domain bait, IR-dependent), in vitro IR kinase assay with GST-FRS2, Co-immunoprecipitation in PC12/IR cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid plus in vitro kinase assay, no clear demonstration that this is a primary physiological mechanism; single lab\",\n      \"pmids\": [\"10650943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FRS2α in hepatocytes is required for FGF15/FGF19-FGFR4 signaling to repress Cyp7a1 expression and limit bile acid production after prandial activity. Ablation of hepatocyte Frs2α alleles abolishes FGFR4-mediated Cyp7a1 regulation.\",\n      \"method\": \"Hepatocyte-specific Frs2α conditional knockout, Cyp7a1 mRNA quantification, FGFR4 gain/loss-of-function experiments\",\n      \"journal\": \"Current molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific knockout with biochemical pathway readout, single lab\",\n      \"pmids\": [\"25056539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FRS2 and Shp2 deletion primarily impairs later lens vesicle development (fiber cell differentiation) rather than lens induction. Shc1 is phosphorylated at Grb2-binding sites downstream of FGF signaling; Shc1 deletion exacerbates the lens vesicle defect caused by Frs2 and Shp2 deletion, establishing Shc1 as a collaborator with Frs2 and Shp2 in recruiting Grb2 to the FGF signaling complex.\",\n      \"method\": \"Conditional knockout of Frs2, Shp2, Shc1 individually and in combination, MAPK signaling assays, lens developmental phenotype analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional knockouts combined with signaling readouts, genetic epistasis with three interacting components\",\n      \"pmids\": [\"40327534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The FRS2 PTB domain folds via a mechanism involving an intermediate; binding to unphosphorylated FGFR1 peptide and phosphorylated TrkB peptide is electrostatic in nature (modulated by ionic strength). Site-directed mutagenesis identified specific residues involved in early and late binding events for each ligand.\",\n      \"method\": \"Equilibrium and kinetic folding assays, kinetic binding experiments at varied ionic strengths, site-directed mutagenesis\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biophysical characterization with mutagenesis, single lab\",\n      \"pmids\": [\"37543351\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FRS2alpha (FRS2) is a lipid-anchored (myristoylated and palmitoylated) scaffold/docking protein that constitutively associates via its PTB domain with the juxtamembrane region of FGF receptors (phosphorylation-independent) and, in a phosphorylation-dependent manner, with activated TrkA/B and RET receptors; upon receptor activation FRS2alpha is multiply tyrosine-phosphorylated, recruiting Grb2 (directly) and Shp2 (directly) to coordinate assembly of a multiprotein complex (including Gab1, Sos, Cbl) that drives sustained Ras/ERK and PI3K/Akt signaling, while MAP kinase-mediated threonine phosphorylation of FRS2alpha and Cbl-mediated ubiquitination of the receptor constitute negative feedback loops; FRS2alpha additionally signals through Src family kinases (to phosphorylate Sprouty2), anchors atypical PKCs, and recruits Rnd1 to modulate RhoA activity, and is required for FGF-dependent processes including embryogenesis, organogenesis (lens, heart, thyroid, kidney), neural progenitor maintenance, angiogenesis/lymphangiogenesis downstream of VEGF receptors, and bile acid homeostasis downstream of FGFR4.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FRS2 (FRS2alpha) is a lipid-anchored docking protein that nucleates assembly of signaling complexes downstream of receptor tyrosine kinases to drive sustained Ras/ERK and PI3K/Akt activation required for development and growth [#0, #3]. Its PTB domain engages two structurally distinct receptor classes by different mechanisms: it binds the juxtamembrane region of FGFR1 constitutively (phosphorylation-independent, entropy-driven) and the NPXpY motifs of activated TrkA/TrkB (pY490) and RET (pY1062) in a phosphorylation-dependent manner, using adjacent but distinct binding pockets that make these interactions mutually exclusive [#1, #9, #29]. Upon receptor activation FRS2alpha is multiply tyrosine-phosphorylated, directly recruiting Grb2 and Shp2 to build a multiprotein complex including Gab1, Sos, and Cbl; the Shp2-binding sites drive sustained ERK and PI3K signaling while Grb2 brings in the E3 ligase Cbl to ubiquitinate the receptor and FRS2alpha as negative feedback [#0, #3, #6]. A second feedback layer operates through MAP kinase/ERK1/2-mediated threonine phosphorylation of FRS2alpha, which dampens its own tyrosine phosphorylation and restrains ERK output, proliferation, and anchorage-independent growth [#7, #11]. Membrane localization is conferred by N-myristoylation coupled to palmitoylation at Cys4/Cys5, which targets FRS2alpha to lipid rafts where signaling assembly occurs [#10, #30]. Genetically, FRS2alpha is essential for embryogenesis and FGF-dependent organogenesis, with Shp2-binding sites specifically required for eye/lens induction, cortical neural progenitor expansion, and pharyngeal organ migration [#3, #13, #15, #17], and it additionally transduces VEGF receptor signals controlling angiogenesis and lymphangiogenesis and FGFR4 signals controlling bile acid homeostasis [#28, #36]. Persistent FRS2 engagement by oncogenic receptor variants drives transformation, making it a node in RTK-driven cancer [#19, #31].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that FRS2 functions as a docking protein whose recruitment of both Shp2 and Grb2 is required to convert transient into sustained ERK signaling and drive differentiation.\",\n      \"evidence\": \"Co-IP, FRS2 point mutagenesis and dominant-negative Shp2 in PC12 differentiation assays\",\n      \"pmids\": [\"9632781\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which individual tyrosines bind Grb2 versus Shp2\", \"Mechanism of receptor engagement not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed FRS2 couples to the NGF receptor TrkA at the same phosphotyrosine as Shc and can functionally reconstitute neuronal differentiation, defining FRS2 as a shared RTK adaptor.\",\n      \"evidence\": \"cDNA cloning, Co-IP of multiple partners, functional rescue in NGF-nonresponsive TrkA mutant cells\",\n      \"pmids\": [\"10092678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Competition with Shc not quantified\", \"FGF receptor binding mode not yet contrasted\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified FRS2 as an anchoring protein for activated atypical PKCs rather than a substrate, expanding its role beyond ERK adaptor functions.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP and in vitro kinase assays with constitutively active PKClambda\",\n      \"pmids\": [\"10383403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological consequence of aPKC anchoring not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved the dual binding logic of the PTB domain: constitutive phosphorylation-independent binding to FGFR1 versus phosphotyrosine-dependent binding to TrkA, with FGFR1 able to sequester FRS2.\",\n      \"evidence\": \"Peptide competition, alanine-scanning mutagenesis, phosphorylation-dependent binding assays\",\n      \"pmids\": [\"10629055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the two modes not resolved here\", \"In vivo relevance of sequestration untested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated FRS2alpha is essential for FGF signaling and embryogenesis, with distinct tyrosine sites mediating distinct responses, establishing its non-redundant developmental role.\",\n      \"evidence\": \"Mouse knockout (E7.0-7.5 lethality), MEF assays for MAPK/PI3K/chemotaxis/proliferation, complex assembly analysis\",\n      \"pmids\": [\"11447289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific requirements not separable in a global null\", \"Site-specific phenotypes only correlative at this stage\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed FRS2 docks on RET at pY1062 and that constitutive engagement by oncogenic RET-PTC drives sustained MAPK, while HSCR loss-of-function mutants impair FRS2 binding, linking FRS2 to RET-driven disease.\",\n      \"evidence\": \"Co-IP, RET Y1062 mutagenesis, oncogenic and loss-of-function mutant panels, MAPK/proliferation assays\",\n      \"pmids\": [\"11390647\", \"11360177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FRS2 selectivity for RAS/MAPK over PI3K only inferred from complex composition\", \"Adaptor competition at Y1062 not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that an alternatively spliced FGFR1 juxtamembrane VT motif is required for FRS2 binding and ERK activation, linking receptor isoform choice to FRS2 coupling.\",\n      \"evidence\": \"Co-IP with VT+/VT- isoforms and ERK2 assays\",\n      \"pmids\": [\"11729184\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Physiological prevalence of VT- isoforms not assessed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Placed FRS2 in a Src-family kinase (Laloo)-FGFR1 complex required for mesoderm induction and axis formation in vivo.\",\n      \"evidence\": \"Xenopus overexpression/dominant-negative, Co-IP with Laloo and FGFR1, Ras epistasis, explant assays\",\n      \"pmids\": [\"11463744\", \"11731233\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase-substrate relationship not fully defined\", \"Model-organism context\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined a MAP kinase-mediated negative feedback loop: ERK phosphorylates FRS2alpha on threonines to suppress its tyrosine phosphorylation, restraining proliferation and transformation.\",\n      \"evidence\": \"Threonine site mutagenesis, in vitro kinase assays, soft-agar and migration/proliferation assays\",\n      \"pmids\": [\"12419216\", \"12974390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and kinetics of feedback in vivo unclear\", \"Specific threonines mapped only partially\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified Grb2-bridged recruitment of the E3 ligase Cbl as a feedback mechanism ubiquitinating FGFR and FRS2alpha, with redundant downregulation routes.\",\n      \"evidence\": \"Co-IP of ternary FRS2-Grb2-Cbl complex, ubiquitination assays, FRS2-null cells\",\n      \"pmids\": [\"11997436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of redundant downregulation pathway unknown\", \"Ubiquitination sites not mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Provided the biophysical basis for dual receptor recognition: enthalpy-driven phosphotyrosine binding to Trk versus entropy-driven phosphorylation-independent binding to FGFR1, with the C-terminal region modulating PTB conformation.\",\n      \"evidence\": \"Isothermal titration calorimetry, NMR, mutagenesis\",\n      \"pmids\": [\"11877385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of FGFR1-bound state not determined here\", \"Functional consequence of C-terminal autoinhibition in cells untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Localized FRS2 to lipid rafts and showed serine/threonine phosphorylation within rafts (PKC/Src/MEK) suppresses tyrosine phosphorylation, integrating membrane microdomain context with feedback regulation.\",\n      \"evidence\": \"Lipid raft fractionation, inhibitor studies, Grb2 co-fractionation\",\n      \"pmids\": [\"12571252\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of raft targeting not yet molecular\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined FRS2 as the intermediary that recruits and activates Src family kinases to phosphorylate Sprouty2, wiring FRS2 into ERK pathway feedback inhibition.\",\n      \"evidence\": \"Src inhibitor, mutant cells, Co-IP of Src-Sprouty2, FRS2-dependent Src activation\",\n      \"pmids\": [\"15564375\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FRS2-Src binding interface not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Used allele-specific knock-in mice to show Shp2-binding (not Grb2-binding) sites on FRS2alpha are required for eye/lens induction via ERK and downstream eye-field genes.\",\n      \"evidence\": \"Frs2alpha 2F/2F vs 4F/4F knock-in mice, IHC, in vivo pERK, marker gene analysis\",\n      \"pmids\": [\"15569927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why Grb2 sites are dispensable here not explained\", \"Cell-autonomy not fully resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended the Shp2-site requirement to cortical neural progenitor proliferation, distinguishing FRS2-dependent proliferation from FGF2-induced self-renewal.\",\n      \"evidence\": \"Frs2alpha 2F knock-in mice, BrdU, neurosphere assays, cortical histology\",\n      \"pmids\": [\"16239343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular distinction between proliferation and self-renewal pathways unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed a non-ERK output: FRS2 binds Rnd1 and, upon Shp2 recruitment displacing Rnd1, modulates RhoA activity to promote neurite outgrowth.\",\n      \"evidence\": \"Direct binding/pulldown, RhoA activity assays, Rnd1 siRNA, PC12 neurite outgrowth\",\n      \"pmids\": [\"15738000\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of Rnd1-RhoA arm untested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Clarified that the FRS2alpha C-terminal region autoinhibits PTB-FGFR1 binding, relieved by receptor kinase activation, and that Grb2 sites mediate FiRE enhancer activation.\",\n      \"evidence\": \"Co-IP with kinase-dead/tyrosine FGFR1 mutants, PTB truncations, reporter assay\",\n      \"pmids\": [\"17901128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conformational mechanism of relief not structurally resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed FRS2 recruits RET to focal complexes to activate Src/FAK and drive migration, with adaptor competition at Y1062 dictating outcome.\",\n      \"evidence\": \"Co-IP, focal complex microscopy, Src/FAK assays, RET Y1062/Y981 mutagenesis, migration assays\",\n      \"pmids\": [\"18189271\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative competition model not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated FRS2alpha (via Shp2 sites) is required for migration but not initial specification of pharyngeal-endoderm organs, separating its roles in morphogenesis from cell fate.\",\n      \"evidence\": \"Frs2alpha 2F/2F mice, staged histology and differentiation marker immunostaining\",\n      \"pmids\": [\"19235715\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Migration effector pathway downstream of FRS2 not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established cell-type-specific requirements for FRS2alpha in cardiac outflow tract development, including progenitor expansion and EndMT.\",\n      \"evidence\": \"Conditional knockout, histology, lineage tracing, immunostaining\",\n      \"pmids\": [\"18832393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor(s) upstream in this context not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed persistent FRS2 engagement by an oncogenic FGFR2 IIIb Y770F variant is required for enhanced transformation, establishing FRS2 as an oncogenic driver node.\",\n      \"evidence\": \"FGFR2 mutagenesis (Y770F/L773A), Co-IP, focus formation assays\",\n      \"pmids\": [\"19103595\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors of the persistent complex not dissected\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified EphA4 as a direct FRS2alpha PTB partner and kinase, forming a ternary EphA4-FGFR-FRS2alpha complex that supports neural progenitor proliferation.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro binding and kinase assays, dominant-negative constructs, NSC proliferation assay\",\n      \"pmids\": [\"20184660\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo requirement of the ternary complex untested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a paracrine FRS2alpha-ERK-Cdx2-Bmp4 axis in trophoblast stem cells supporting inner cell mass growth.\",\n      \"evidence\": \"Frs2alpha-null ES/TS cells, ChIP on Bmp4 promoter, Bmp4 rescue, ERK assays\",\n      \"pmids\": [\"19890878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability beyond TS cells unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Linked FRS2alpha-FGF signaling to autophagy suppression via PI3K/Akt/mTOR, with loss promoting premature cardiac progenitor differentiation.\",\n      \"evidence\": \"Conditional knockout and Frs2alpha-null MEFs, LC3 assays, PI3K/Akt/mTOR inhibitors\",\n      \"pmids\": [\"22207710\", \"21927580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between FRS2 and mTOR not mapped\", \"Single lab cluster\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended FRS2alpha function to VEGF receptor signaling, showing it is required in endothelium for angiogenesis, lymphangiogenesis, and arteriogenesis.\",\n      \"evidence\": \"Endothelial-specific conditional knockout, in vitro VEGF signaling, in vivo vascular phenotyping\",\n      \"pmids\": [\"24706887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct VEGFR-FRS2 binding mode not characterized\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established FRS2alpha as the hepatocyte adaptor required for FGF15/19-FGFR4 repression of Cyp7a1 and bile acid homeostasis.\",\n      \"evidence\": \"Hepatocyte-specific knockout, Cyp7a1 mRNA quantification, FGFR4 gain/loss-of-function\",\n      \"pmids\": [\"25056539\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream transcriptional effectors of Cyp7a1 repression not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Provided structural confirmation of two distinct adjacent PTB binding pockets enabling mutually exclusive FGFR versus Trk engagement.\",\n      \"evidence\": \"NMR structure of PTB bound to phosphorylated TrkB, binding pocket analysis\",\n      \"pmids\": [\"24470253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FGFR-bound structure complementary to TrkB structure not solved\", \"Allosteric coupling between pockets unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed FRS2 drives neurotrophin-induced neurite outgrowth through both Grb2 and Shp2 pathways, with Grb2 bridging to Gab1/Gab2 and PI3K, and that FRS3 cannot substitute.\",\n      \"evidence\": \"Adenoviral FRS2 mutant overexpression in primary cortical neurons, neurite quantification, Gab1/Gab2 Co-IP\",\n      \"pmids\": [\"25159185\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis for FRS3 inability not explained\", \"Overexpression context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the membrane-anchoring mechanism: coupled N-myristoylation and Cys4/Cys5 palmitoylation are required for plasma membrane localization, with myristoylation a prerequisite for palmitoylation.\",\n      \"evidence\": \"Palmitoylation assays, G2A/C4A/C5A mutagenesis, fluorescence fluctuation spectroscopy\",\n      \"pmids\": [\"31184863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the palmitoyltransferase unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed pharmacological inhibition of FRS2alpha myristoylation suppresses FGFR-driven oncogenic signaling and tumorigenesis, nominating membrane anchoring as a therapeutic target.\",\n      \"evidence\": \"N-myristoyltransferase inhibitor B13, phosphorylation assays, xenograft model, FGFR inhibitor combination\",\n      \"pmids\": [\"29540482\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"B13 specificity for FRS2 versus other myristoylated proteins not isolated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified FRS2alpha as a developmental-stage-specific controller of EndMT, restraining TGFbeta signaling in a let-7-dependent manner.\",\n      \"evidence\": \"Inducible endothelial-specific knockout at E7.5 vs E10.5, histological/molecular AV valve analysis\",\n      \"pmids\": [\"31669335\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking FRS2 loss to let-7/TGFbeta not fully defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Characterized the folding pathway and electrostatic, ionic-strength-dependent binding kinetics of the PTB domain for both FGFR1 and TrkB ligands.\",\n      \"evidence\": \"Equilibrium/kinetic folding and binding assays at varied ionic strength, site-directed mutagenesis\",\n      \"pmids\": [\"37543351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular relevance of folding intermediate unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Refined the lens model: FRS2 and Shp2 act mainly in fiber cell differentiation, and Shc1 collaborates with them to recruit Grb2, defining a partially redundant Grb2-recruitment module.\",\n      \"evidence\": \"Combinatorial conditional knockouts of Frs2/Shp2/Shc1, MAPK assays, lens phenotyping\",\n      \"pmids\": [\"40327534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each adaptor to Grb2 recruitment unresolved\", \"Generalizability to other tissues untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the lipid-raft-anchored FRS2alpha integrates the multiple competing inputs (FGFR, Trk, RET, VEGFR, EphA4) into context-specific ERK versus PI3K versus RhoA outputs, and the structural mechanism by which C-terminal autoinhibition and threonine feedback are dynamically tuned, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No full-length FRS2alpha structure in a receptor-bound signaling complex\", \"Quantitative model of adaptor competition and feedback dynamics lacking\", \"VEGFR and EphA4 binding modes not structurally defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 3, 6, 33]},\n      {\"term_id\": \"GO:0005515\", \"supporting_discovery_ids\": [1, 9, 29]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 11, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 30, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 4, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 13, 15, 17, 18]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [22, 23]}\n    ],\n    \"complexes\": [\"FRS2alpha-Grb2-Cbl complex\", \"FRS2alpha-Grb2-Sos1-Shp2 complex\", \"EphA4-FGFR-FRS2alpha ternary complex\"],\n    \"partners\": [\"GRB2\", \"PTPN11\", \"CBL\", \"GAB1\", \"RET\", \"FGFR1\", \"RND1\", \"SRC\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}